 
 Protocol Title:  A Phase 2A, Placebo-controlled, Randomized, 
Dose Response Study of the Safety, 
Pharmacokinetics and Efficacy of PCS12852 
on Gastric Emptying Rate Assessed by 13C 
Spi[INVESTIGATOR_752873] 3.0, [ADDRESS_1030758] Number [STUDY_ID_REMOVED] 
 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      1 of 85    20 April 2022  Title Page  
Protocol  Title:  A Phase 2A , Placebo -controlled, Randomized , Dose Response 
Study of the Safety, Pharmacokinetics and Efficacy of PCS12852 
on Gastric Emptying Rate Assessed by 13C Spi[INVESTIGATOR_752874] : PCS12852  
Indication:  Moderate to Severe Gastroparesis  
Study Sponsor:  Processa Pharmaceuticals, Inc.  
[ADDRESS_1030759] Hanover MD [ZIP_CODE]  
Protocol  Number.:  PCS12852 -GP-01 
Study Phase:  2A 
IND number  154163  
Version:  3.0 
Approval Date : [ADDRESS_1030760] of Tabl es ................................................................................................................................... 5 
1 Protocol Summary .................................................................................................................... 6 
1.1 Synopsis  ................................................................................................................................ 6 
1.2 Schedule of Activities (SoA)  .............................................................................................. 17 
2 Introduction............................................................................................................................. 20 
2.1 Study Rationale ................................................................................................................... 21 
2.2 Back ground  ......................................................................................................................... 22 
2.3 Benefit/Risk Assessment  .................................................................................................... 26 
3 Objectives and Endpoints  ....................................................................................................... 28 
4 Study Design ........................................................................................................................... 30 
4.1 Overall Design  .................................................................................................................... 30 
4.2 Scientific Rationale for Study Design  ................................................................................ 31 
4.3 Justification for Dose  .......................................................................................................... 32 
4.4 End of Study Definition ...................................................................................................... 32 
5 Study Population  ..................................................................................................................... 33 
5.1 Inclusion Criteria  ................................................................................................................ 33 
5.2 Exclusion Criteria  ............................................................................................................... 34 
5.3 Lifestyle Considerations  ..................................................................................................... 36 
5.3.1  Meals and Dietary Restrictions  ...................................................................................... 36 
5.4 Screen Failures  ................................................................................................................... 36 
6 Study Treatment and Concomitant Therapy  ........................................................................... 37 
6.1 Treatments Administered  .................................................................................................... 37 
6.2 Preparation, Handling, Storage, and Accountability .......................................................... 37 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................................ 38 
6.4 Study Treatment Compliance  ............................................................................................. 39 
6.5 Continued Access to Study Treatment After the End of the Study ..................................... 39 
6.6 Treatment of Overdose  ....................................................................................................... 40 
6.7 Concomitant Therapy  ......................................................................................................... 40 
6.7.1  Prohibited Treatments  ..................................................................................................... 40 
6.7.2  Permitted Treatments  ...................................................................................................... 41 
6.7.3  Rescue Medicine  ............................................................................................................ 42 
7 Discontinuation/Withdrawal Criteria  ...................................................................................... 42 
7.1.1  Stoppi[INVESTIGATOR_2121]  ............................................................................................................ 43 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      4 of 85    20 April 2022  7.2 Loss to Follow -Up/Early Discontinuation from Study Drug  ............................................. 44 
8 Study Assessments and Procedures  ........................................................................................ 44 
8.1 Efficacy Assessments .......................................................................................................... 45 
8.1.1  Primary Efficacy Assessment – Gastric Emptying Breath Test  ...................................... 45 
8.1.2  Secondary Efficacy Assessment – ANMS GCSI -DD..................................................... 46 
8.1.3  Exploratory Efficacy Assessments  ................................................................................. 47 
[IP_ADDRESS]  PAGI -SYM and PAGI -QOL  ....................................................................................... 47 
[IP_ADDRESS]  CGI-S and CGI -I ......................................................................................................... 48 
[IP_ADDRESS]  PGI-S and PGI -C ........................................................................................................ 48 
8.2 Safety Assessments  ............................................................................................................. 49 
8.2.1  Physical Examinations  .................................................................................................... 49 
8.2.2  Vital Signs  ...................................................................................................................... 50 
8.2.3  Electrocardiograms  ......................................................................................................... 50 
8.2.4  Clinical Safety Laboratory Tests  .................................................................................... 50 
8.2.5  Pregnancy Testing ........................................................................................................... 51 
8.2.6  Suicidal Ideation and Behavior Risk Monitoring ........................................................... 51 
8.3 Adverse Events, Serious Adverse Events, and Other Safety Reporting ............................. 52 
8.3.1  Time Period and Frequency for Collecting AE and SAE Information  ........................... 52 
8.3.2  Method of Detecting AEs and SAEs  .............................................................................. 52 
8.3.3  Follow -up of AEs and SAEs  ........................................................................................... 53 
8.3.4  Regulatory Reporting Requirements for SAE  ................................................................ 53 
8.3.5  Pregnancy  ....................................................................................................................... 53 
8.4 Pharmacokinetics  ................................................................................................................ 54 
9 Statistical Considerations ........................................................................................................ 55 
9.1 Analysis Sets ....................................................................................................................... 55 
9.2 Statistical Analyses  ............................................................................................................. 55 
9.2.1  General Considerations  .................................................................................................. 55 
9.2.2  Primary Efficacy Analysis  .............................................................................................. 55 
9.2.3  Secondary Efficacy Analysis  .......................................................................................... 57 
9.2.4  Other Patient -reported outcomes (PRO) Assessments – Exploratory Endpoints  ........... 57 
9.2.5  Safety Analyses  .............................................................................................................. 58 
9.3 Sample Size Determination  ................................................................................................ 59 
10 Supporting Documentation and Operational Considerations  ................................................. 60 
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ............................. 60 
10.1.1  Regulatory and Ethical Considerations  .......................................................................... 60 
10.1.2  Informed Consent Process  .............................................................................................. 61 
10.1.3  Data Protection  ............................................................................................................... 61 
10.1.4  Dissemination of Clinic al Study Data  ............................................................................ 62 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      5 of 85    20 April 2022  10.1.5  Data Quality Assurance  .................................................................................................. 62 
10.1.6  Source Documents  .......................................................................................................... 63 
10.1.7  Study and Site Start and Closure  .................................................................................... 63 
10.1.8  Protocol Approval and Amendment  ............................................................................... 64 
[IP_ADDRESS]  Access to Source Data  ................................................................................................ 64 
10.2  Appendix 2: Clinical Laboratory Tests  ............................................................................... 66 
10.3  Appendix 3: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting ................................................................................................... 68 
10.3.1  Definition of AE  ............................................................................................................. 68 
10.3.2  Definition of SAE  ........................................................................................................... 69 
10.3.3  Recording and Follow -up of AE and SAE  ..................................................................... 71 
10.3.4  Reporting of SAE  ........................................................................................................... 74 
10.4  Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information .............. 76 
Definitions ..................................................................................................................................... 76 
10.5  Appendix 5: Abbreviations  ................................................................................................. [ADDRESS_1030761] of Tables  
Table 1  Schedule of Activities (SoA)  ................................................................................ 17 
Table 2  Objectives and Endpoints  ..................................................................................... 28 
Table 3  Study Treatments Administered  ............................................................................ 37 
Table 4  Measures to Minimize Bias  .................................................................................. 38 
Table 5  Analysis Data Sets  ................................................................................................ 55 
Table 6  Protocol -required Safety Laboratory Tests  ........................................................... 66 
 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      6 of 85    20 April 2022  1 Protocol Summary 
1.1 Synopsis  
Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
Title of Study: A Phase 2A Placebo -controlled, R andomized D ose R esponse S tudy of the 
Safety , Pharmacokinetics  and Efficacy of PCS12852 on Gastric Emptying Rate A ssessed by 
13C Spi[INVESTIGATOR_752875].  
Study center(s):  Approximately 8 centers in  the [LOCATION_002] ( US) 
Phase of Development: Phase 2a  
Objectives:  
Primary Objective:  
• To evaluate the effect of different doses of PCS12852 on the gastric emptying rate, as 
measured by [CONTACT_752885]  (GEBT) , in patients with moderate  to 
severe idiopathic gastroparesis (IG) or diabetic gastroparesis  (DG).  
• To evaluate the safety and tolerability of different doses of PCS [ZIP_CODE] i n IG and DG 
patients.  
• To evaluate the PK profile of PCS12852 at different dose levels. 
Secondary Objective:  
• To eval uate the effect of different doses of PCS12852 on symptoms, as measured by [CONTACT_752886] ( ANMS GCSI -DD), in patients with moderate to severe IG or DG.  
Methodology:  
This is a randomized, double -blind, placebo- controlled study that will compare the effect of 
[ADDRESS_1030762] successfully completed Screening 
criteria (Visit 1) will return for a second Screening Visit (Visit 2) where the 
inclusion/exclusion criteria will be re -evaluated. Visit 1 will include all safety labs and 
procedures (including an electrocardiogram [ ECG ]). The investigator  will complet e the 
Columbia -Suicide Severity Rating Scales  (C-SSRS) to confirm that the re are no suicidal 
tendencies or ideation.  If the  patients still meet study criteria when returnin g for Visit 2, 
patients will have a GEBT performed and will be educated on completion of the ANMS 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      7 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
GCSI -DD. Patients will complete  the ANMS GCSI -DD for  7 days. The results from both the 
GEBT and the ANMS GCSI -DD during the Screening period will be considered the b aseline 
values for these assessments.  
Patients will return to the site for Visit 3 (Randomization) where patients who meet the 
criteria based on having moderate to severe symptoms based on the ANMS GC SI-DD and 
moderate to severe delay in gastric emptying will be randomized in a 1:1:1 ratio into three 
treatment groups, PCS12852 0.1 mg, PCS12852 0.5 mg or placebo.  
At Visit 3, patients will answer a series of assessments including the following: Patient 
Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI -SYM), Patient 
Assessment of Upper Gastrointestinal Disorders – Quality of Life (PAGI -QOL), Patient 
Global Impression of Severity (PGI -S) and the Patient  Global Impression of Change (PGI -C). 
Patients will arrive fasting and have PK samples drawn prior to receiving the first dose and at 
the following times after the first dose : 0.5, 1, 2, 4, 6, and 8 hours. The investigator will 
assess the patient through t he C-SSRS as well as the Clinical Global Impression - Severity 
scale (CGI -S) and Clinical Global Impression – Improvement scale (CGI -I). 
Patients will take their assigned treatment for [ADDRESS_1030763] 30 minutes 
prior to a meal (actual dosing times will be captured via a dosing diary) , starting on Day [ADDRESS_1030764] -dose. The ECG should be performed prior 
to the 4- hour PK draw between the 2-  and 4-  hour samples. The patient ’s fasting blood 
glucose (FBG) of ≤ 275 mg/dL is required to proceed with the GEBT. If the patient’s FBG is 
not within range, the patient wil l be sent home with an additional dose of study drug and 
asked to return the next day to perform  the GEBT.  The GEBT test will be performed for 4 
hours  and will be administered approximately 30- 60 minutes after the patient’s final dose of 
study treatment . During the GEBT test, the site will prioritize taking the GEBT samples and 
then the PK samples. After the test is complete the patients will be discharged and will return  
approximately 48- 72 hours after Day 28  (Visit 6)  to have a PK blood sample drawn. The 
patient will also return to the site 1 week after the Day 28 visit for a follow -up visit  (Day 
35/Visit 8) . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      8 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ADDRESS_1030765] a fasting blood glucose  
(FBG)  of ≤  275 mg/dL  to proceed with the GEBT. If the patient does not have a FBG of ≤ 
275 mg/dL prior to the GEBT, the patient may come in the following day to take the GEBT. The GEBT is a nonradioactive , noninvasive  test that measures  gastric emptying. Patients 
provide baseline (premeal)  breath  samples and then consume a standardized 230 kCal 
(kilocalorie) meal, consisting of a proprietary standardized 
13C labeled egg component 
(which is rehydrated and then microwaved for 1.5 minutes) and [ADDRESS_1030766] the stomach empties the meal by [CONTACT_145414] -13 dioxide 
(13CO 2) excretion arising from the digested test  meal. The rate of 13CO 2 excretion found in 
the patient's  breath  is proportional to the patient's rate of gastric emptying. 
The total study duration for each patient will be approximately 8 weeks.  
Number of patients (planned):  
Total number randomized into this study: [ADDRESS_1030767] documented delayed gastric emptying. The randomization to treatment groups will 
be stratified by [CONTACT_24975] ( IG, DG), enrolling at least 2  patients of each type  in each treatment 
group. 
Diagnosis and Main criteri a for Eligibility:  
Inclusion criteria:  
1. Has a documented diagnosis of moderate to severe IG or DG  according to the ANMS 
GCSI -DD score during the Screening Period (Score of > 2 on average of the 
screening days) . 
2. Moderate to severe delay in gastric emptying rate as measured by [CONTACT_752887] -time (t1/2) ≥ the 80th percentile of normative data as determined 
by [CONTACT_752888] . 
3. Male or female patients 18 to 80 years of age, inclusive, at baseline.  
4. Has continuous moderate to severe symptoms for gastroparesis  (that is, chronic 
postprandial fullness, abdominal pain, postprandial nausea, vomiting, loss of appetite 
and/or early satiety) as assessed by [CONTACT_752889] 3 months . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      9 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
5. Has hemoglobin A1c (H bA1c) less than (<) 1 1%. 
6. Has Body Mass Index (BMI) range between [ADDRESS_1030768] use one of the following acceptable methods of contraception throughout the study (from [ADDRESS_1030769] dose of study medication) : oral contraceptive medication, intrauterine 
device (IUD), hormonal implants, injectable contraceptive medications, double -barrier methods, or tubal ligation. 
9. Females who are postmenopausal (age- related amenorrhea ≥ 12 consecutive months 
and increased follicle- stimulating hormone [FSH] > 40 mIU/mL. If necessary, to 
confirm postmenopausal status, an FSH will be drawn at Sc reening) or who have 
undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing.  
10. Male patients must be willing to use acceptable contraceptive measures such as 
vasectomy or double barrier method and refrain from sexual activity with  any female 
who is pregnant or lactating. Female partners of male participants should use acceptable methods of contraception stated in Inclusion #[ADDRESS_1030770] be willing and able to comply with study procedures.  
13. Compliance with the completion of the ANMS GCSI -DD, defined as approximately 
80% diary completions, during the screening period. For those patients whose 
compliance is measured to be <80%, the final decision to randomize a patient will be 
made by [CONTACT_2725] (or designee).  
14. Patient must be willing and able to provide signed, informed consent.  
Exclusion criteria:  
1. Has acute, severe gastroenteritis and pronounced dehydration in the past 48 hours 
prior to Screening, chronic parenteral feeding or persistent severe vomiting. 
2. Has known hypersensitivity to Spi[INVESTIGATOR_112174], egg, milk products  or wheat allergens.  
3. Has a known disturbance of small intestinal absorption, exocrine pancreatic function, liver metabolism or pulmonary function.  
4. Has a history of anorexia nervosa or bulimia.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      10 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
5. Previous history of bezoars (the presence of retained liquid, bile, or small amounts  of 
poorly organized food residue is permitted). 
6. Prior surgery involving any gastrointestinal (GI) surgery, including the luminal GI 
tract (cholecystectomy  and appendectomy, are permitted if performed greater than [ADDRESS_1030771]).  
7. Any abdominal or pelvic surgery within the past 3 months. 
8. Known or history of the following GI conditions: inflammatory bowel disease ; 
irritable bowel syndrome with diarrhea; or any other active disorder that could explain symptoms in the opi[INVESTIGATOR_871] . 
9. Has active diverticulitis, diverticular stricture, and other intestinal strictures.  
10. Has feeding or decompression tubes  and/or a gastric pacemaker . 
11. Has had Botox pyloric injection s within the prior 3 months . 
12. Has had diabetic ketoacidosis ( within the prior 4 weeks).  
13. Currently taking Glucagon- like peptide -1 (GLP -1) agonists , e.g. exenatide, 
liraglutide, semaglutide or dulaglutide;  or pramlintide.  
14. Has severe psychiatric illness (including suicidal tendencies or ideation) or neurological illnes s. 
15. History or suspi[INVESTIGATOR_752876], barbiturate, amphetamine or narcotic abuse.  
16. Use of narcotics/opi[INVESTIGATOR_2438], drugs used to treat gastroparesis within [ADDRESS_1030772].  
17. Anticipated concurrent use of a strong Cytochrome P450 ( CYP ) inhibiting or  
inducing drug (listed in Section 6.7.1)  that would significantly alter the metabolism of 
PCS12852 and/or its metabolites during the course of the study (after Screening)  
18. Fever (>38°C), or chronic, persistent, or recurring infection(s) at Screening or baseline.  
19. Clinically significant cardiac dise ase including but not limited to unstable angina, 
acute myocardial infarction within 6 months of baseline, and arrhythmia requiring therapy.  
20. Patient has QTcF  interval ≥ 480 milliseconds on Screening ECG; a second Screening 
ECG may be done at the I nvestigat or’s discretion but the average of the two QTc F 
screening intervals must not be ≥ 480 milliseconds. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      11 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
21. History of cerebral hemorrhage, cerebrovascular accident, transient ischemic attack, 
gastrointestinal bleeding, or retinal hemorrhage within 6 months of bas eline.  
22. Patient has active or history of neoplastic disease (except for adequately treated non -
invasive basal cell and/or squamous cell carcinoma of the skin or carcinoma in situ of 
the cervix) within the past 5 years prior to baseline.  
23. Presence of clinical ly significant medical condition(s) including but not limited to: 
renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, pulmonary, 
neurological, psychiatric, substance abuse, and/or any other clinically significant 
disease or disorder , which in the opi[INVESTIGATOR_689] (by [CONTACT_752890]), may put the patient at risk due to participation in the study, 
influence the results of the study, and/or affect the patient’s ability to complete the 
study. 
24. History of or current diagnosis of active tuberculosis (TB); undergoing treatment for 
latent TB infection (LTBI); untreated LTBI (as determined by [CONTACT_53803] [ADDRESS_1030773] with purified protein derivative with induration >= [ADDRESS_1030774] or positive or 
borderline T -SPOT [Elispot] test); or positive TB test at Screening.  Patients with 
documented completion of appropriate LTBI treatment would not be excluded and are not required to be tested.  
25. Vaccination with live or live -attenuated virus vaccine within 1 month prior to 
baseline.  Vaccines for COVID -19 are allowed.  
26. The results of the following laboratory tests performed at the central laboratory at Screening meet any of the criter ia below:  
a. Hemoglobin < 8.0 g/dL (International System of Units: < 80 g/L)  
b. White blood cells < 3.0 x 10^3 cells/mm^3 (SI: < 3.0 x 10^9 cells/L)  
c. Neutrophils < 1.0 x 10^3 cells/mm^3 (SI: < 1.0 x 10^9 cells/L)  
d. Lymphocytes < 0.5 x 10^3 cells/mm^3 (SI: < 0.5 x 10^9 cells/L)  
e. Platelets < 100 x 10^3 cells/mm^3 (SI: < 100 x 10^9 cells/L)  
f. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or 
alkaline phosphatase (ALP) ≥ 2 x upper limit of normal (ULN)  
g. Total bilirubin level ≥ [ADDRESS_1030775] unless the individual has been diagnosed with Gilbert's disease and this is clearly documented  
h. Estimated glomerular filtration rate < 40 mL/min/1.73 m^2 based on the Modification of Diet in Renal Disease formula  
i. Creatinine  ≥ 3 mg/dL  
j. Positive human immunodeficiency vi rus serology  
k. Evidence of active Hepatitis B Virus infection  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      12 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ADDRESS_1030776] 30 minutes prior to a meal)  during 
the treatment period of the study. The patient will be asked to complete a dosing diary to 
document actual dosing times. Group  Dosage Forms  
PCS12852  0.1 mg  tablet  
PCS12852  0.5 mg tablet  
Placebo  Matching tablet  
Criteria for Evaluation:  
Primary Endpoint s 
• Change in gastric emptying rate from baseline as determined by [CONTACT_752891] 6 (Day 28)  after administration 
of the  PCS12852 or placebo. 
• Change in gastric emptying rate from baseline using the t
10 and t 50 metric for gastric 
emptying rate.  
• Concentrations of PCS [ZIP_CODE] in plasma; PK parameters will be estimated from 
concentration -time data using noncompartmental methods, as data permit.  
Secondary Endpoints  
• Change from baseline in the ANMS GCSI -DD ( i.e., Day -7 to Day -1) (predose) and Day 
7 (Day 1 to Day 7) . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      13 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
• Change from baseline in the ANMS GCSI -DD ( i.e., Day-7 to Day -1) (predose) and Day 
14 (Day 8 to Day 14) . 
• Change from baseline in  the ANMS GCSI -DD ( i.e., Day -7 to Day -1) (predose) and Day 
21 (Day 15 to Day 21) . 
• Change from baseline in  the ANMS GCSI -DD ( i.e., Day -7 to Day -1) (predose) and Day 
28 (Day 22 to Day 28 ). 
Exploratory Endpoints  
• Change from baseline in ANMS GCSI -DD score over time (Day 7, 14, 21, 28) by 
[CONTACT_508203] 7 to Day 14, Day 14 to Day 21 and Day 21 to Day 28.  
• Change from baseline in the subscores (naus ea, early satiety, postprandial fullness, 
upper abdominal pain and number of vomiting epi[INVESTIGATOR_1841]) of the ANMS -GCSI -DD 
over time (Day 7, 14 ,21, 28) by [CONTACT_508203] 7  to Day  14, Day 14 to Day 21 and 
Day 21 to Day 28.  
• Change from baseline in PAGI -SYM and PAGI -QOL scores over time by [CONTACT_752892] 1 to Day 28.  
• Change from baseline in Clinical Global Impression -Severity ( CGI-S) and Clinical 
Global Impression -Improvement ( CGI-I) scores over time by [CONTACT_508203] 1 to 
Day 28. 
• Change from baseline in PGI -S and PGI -C scores over time by [CONTACT_508203] 1 to 
Day 28. 
Safety  Endpoints  
• Adverse E vents (AEs) (by [CONTACT_24975], severity, and relatedness) at each visit.  
• Changes in safety clinical laboratory testing and  vital signs at each site visit.  
• Changes in ECGs  at each site visit  and the potential correlation of the PK with changes in 
the ECG.  
• Change from baseline in the C -SSRS scores over time by [CONTACT_508203] 1 to Day 28. 
STATISTICAL ANALYSES:  
Analysis  Sets : 
• Safety Set: A ll patients enrolled in the study who received at least 1 dose of treatment.  
• PK Analysis Population:  Patients in the Safety Set with at least 1  plasma sample with a 
quantifiable concentration of PCS12852.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      14 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
• Full Analysis Set (FAS): All patients who are rand omized.  
Other populations (e.g., Per Protocol) may be defined and used as supportive evidence of 
treatment benefit.  
Patient Characteristics:  
Baseline demographics and disease characteristics will be presented for each treatment group 
by [CONTACT_9086]. All descriptive summary statistics of continuous variables will 
include n, me an, median, standard deviation (SD), minimum and maximum. All descriptive 
summaries presenting frequencies and i ncidences will include n, percent of total, and N, 
where N is the total number of patients with recorded values in the corresponding group. Patient completion status and exposure outcomes will be similarly presented. 
Primary Efficacy Analyses:  
The change in the gastric emptying rate AUC from baseline to Day 28 will b e analyzed in the 
FAS using an analysis of covariance (ANCOVA) model with treatment group (three levels) and types (IG, DG)  as a factor and the baseline GEBT as a covariate. Each of the two 
primary comparisons (0.1 mg versus placebo, 0.5 mg versus placebo)  will be conducted 
using a two- sided Dunnett’s test at the overall alpha=0.05 significance level .  
Other efficacy analyses:  
All secondary endpoints will be analyzed using the same types of ANCOVA models as 
described for the primary analysis. Each treated group will be compared to placebo. All 
secondary analyses will be conducted with no adjustment for multiplicity.  
Subgroup ana lysis:  
A subgroup analysis of idiopathic gastroparesis patients compared to diabetic gastroparesis 
patients will be performed  for all efficacy analysis endpoints.  
Pharmacokinetic Assessment  
Plasma concentrations will be used to estimate the pharmacokinetic parameters for 
PCS12852 on Day 1 and Day 28 using noncompartmental methods  in WinNonlin®. The 
following parameters will be calculated  as data permit:  
• Cmax: maximum observed plasma concentra tion 
• Tmax: time at which the maximum plasma concentration was observed  
• t½: (the apparent first -order terminal elimination half -life) 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      15 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
• AUC 0-last: the area under the plasma concentration versus time curve, from time [ADDRESS_1030777] measurable concentration  
• AUC ∞: the area under the plasma concentration vs. time curve from time 0 to infinity  
• λz: apparent first order terminal elimination rate constant 
A dose proportionality analysis will be conducted for log- transformed C max, AUC 0-last, and 
AUC ∞ using the power model.   In addition, the relationship between gastric emptying rate and 
drug exposure will be assessed, as data permit.  Exposure -response for safety measures may 
also be explored.  Details of these analysis will be provide d in the Statistical Analysis Plan.  
In addition, a population PK model may be used to describe the PK of PCS12852, if 
appropriate based on the data collected.    A previously developed population PK model 
describing the PK of PCS12852 in patients with functional constipation, using a two-
comp artment model with first order absorption, may be used to predict the PK in patients in 
this study.  
 
Safety Analyses:  
The safety analyses will be performed using the Safety Population and include AEs , changes 
in physical exam findings, vital signs, ECGs and clinical laboratory  values.  
Adverse events will be coded using the current version of the Medical Dictionary for 
Regulatory Activities (MedDRA version 23.0 or higher). The number and percent of patients 
reporting at least one AE will be summarized by [CONTACT_1196] (SOC) and Preferred 
Term (PT) and presented by [CONTACT_926], relationship to study treatment , amount of dr ug 
exposure, and time. Each patient will contribute only once (i.e., first occurrence) to each of 
the incidence rates, regardless of the number of occurrences.  Severity of AEs will be assessed 
based on the National Cancer Institute (NCI) CTCAE Version 5.0. For reporting of AE  
severity in patients with more than one occurrence of the same AE, the patient will only be 
reported once based on the highest severity of the AE  observed. Patients who have a serious 
adverse event (SAE) or who discontinue the study due to an AE  deemed to be related to 
study treatment  will be described in patient narratives.  
Vital signs, clinical laboratory, and ECG results will also be presented and summarized by [CONTACT_752893].  All safety data collected in the clinical database, including physical exam 
findings and abnormal ECG results, will be presented in data listings. 
 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0      16 of 85    20 April 2022  Name [CONTACT_790]/Company: Processa Pharmaceuticals, Inc.  
Name [CONTACT_791]: PCS [ZIP_CODE] 
Name [CONTACT_3261]: PCS [ZIP_CODE] 
SAMPLE SIZE CALCULATION:  
Based on the results of a prior study (Study 102), estima tes of the SD  of the AUC of the 
gastric emptying rate over time as assessed  by [CONTACT_752894] [ADDRESS_1030778] at the alpha=0.025 level of 
significance, a sample size of 8 patients per arm (24 total patients) will provide 80% power to 
detect a between -group mean difference of 25.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0 17 of 85 20 April 2022  1.2 Schedule of Activities  (SoA)  
Table 1  Schedule of Activities (SoA)  
Procedure  Visit 1 
(Screening)  
 Visit 2  
(Screening)  
(Baseline)  Visit 3  
(Randomization)  
Day 1  Visit 4  
Day 7  
 Visit 5  
Day 14  
 Visit 6  
Day 28 
  Visit 7  
48-72 hrs after 
Day 28 visit  Visit 8/ET  
Day 35  
 
Visit Window  Days -21 to -1 ±2 days +3 days +1 day  ±1 day 
Informed consent  X        
Demographic 
information  X        
Medical history  X        
Inclusion/  
Exclusion  criteria  X X X      
Screening Lab 
testing (inc. Hep 
B/C, HIV and TB)  X        
Concomitant 
Medications  X X X X X X  X 
Vital signs  X X X X  X  X 
Physical examg X  X X X X  X 
13C GEBT   X    Xd   
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0 18 of 85 20 April 2022  Procedure  Visit 1 
(Screening)  
 Visit 2  
(Screening)  
(Baseline)  Visit 3  
(Randomization)  
Day 1  Visit 4  
Day 7  
 Visit 5  
Day 14  
 Visit 6  
Day 28 
  Visit 7  
48-72 hrs after 
Day 28 visit  Visit 8/ET  
Day 35  
 
Visit Window  Days -21 to -1 ±2 days +3 days +1 day  ±1 day 
ANMS GCSI -DDa  X X X X X   
Safety laboratory 
testing     X  X  X 
Pregnancy testb X  X X X X  X 
ECGh X  Xi Xj Xj X  X e 
C-SSRS  X  X X X X  X 
PGI-S   X   X  X 
PGI-C   X   X  X 
PAGI -SYM    X   X   
PAGI -QOL    X   X   
CGI -S    X   X  X 
CGI -I   X   X  X 
Adverse  
Events  X X X X X X  X 
Study Drug 
Dispensed    X X X X   
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL  
 
Version 3.0 19 of 85 20 April 2022  a. ANMS GCSI -DD will be collected for 7 consecutive days  after Screening Visit 2, but  prior to randomization (i.e. from Days - 7 to -1) as well as from Day 1 to Day 28.  
b. For WOCBP: Serum β-HCG at Screening Visit 1; Urine pregnancy test at subsequent visits  
c. Patients will take the  dose of PCS12852 or placebo in clinic on Day 28. 
d. A blood glucose finger stick will be taken both before and at the completion of the GEBT . 
e. Repeat ECG at Visit 8 , only if ECG at Visit 6 was abnormal.  
f. PK blood samples will be drawn at both Visit 3  (Day 1)  and Visit 6 ( Day 28) at the following timepoints: pre -dose (trough) and at 0.5h, 1h, 2h, 4h, 6h and 8h post dose.  Clinical staff are 
encouraged to take the blood samples for PK analysis at the scheduled time point; however, deviations from the scheduled samp le times are not considered protocol deviations.  The exa ct 
time and date of the blood draw must be recorded.  
g. A symptom drive n physical exam will be done on Visit 3 ( Day 1 ), Visit 4 (Day 7), Visit 5 (Day 14)  and Visit 8  (Day 35) . 
h. Clinical staff are encouraged to perform ECGs prior to any blood draws at a given v isit. 
i. ECGs should be performed prior to the 4 hour PK draw . 
j. ECGs should be performed approximately 4 hours after patient’s dose . 
k. The single PK sample drawn between 48 -72 hours after the Day 28 visit can either be done in the office or by a home health nurse.Procedure  Visit 1 
(Screening)  
 Visit 2  
(Screening)  
(Baseline)  Visit 3  
(Randomization)  
Day 1  Visit 4  
Day 7  
 Visit 5  
Day 14  
 Visit 6  
Day 28 
  Visit 7  
48-72 hrs after 
Day 28 visit  Visit 8/ET  
Day 35  
 
Visit Window  Days -21 to -1 ±2 days +3 days +1 day  ±1 day 
Study Drug 
Instructions  X X X      
Study Drug 
Administered    X   Xc   
PK samplef   X   X Xk  
Drug Accountability     X X X   
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     20 of 85    20 April 2022  2 Introduction  
Gastroparesis is a disorder character ized by [CONTACT_752895] a mechanical obstruction, particularly pyloric stenosis (  Camilleri, 2013 ). This delay may 
result in the cardinal symptoms of early satiety, postprandial fullne ss, nausea, vomiting, belching 
and bloating. The syndrome is caused by [CONTACT_752896] ( Camilleri, 2018 ). 
Gastroparesis can be idiopathic, associated with diabetes mellitus, can occur after a medical intervention (iatrogenic or post -surgical), may  be associated with neurological disorders or may 
occur after a bacterial or viral infection. In one series of 146 patients, the etiology of gastroparesis was 36% idiopathic, 29% diabet ic, 13% postsurgical, 7.5% Parkinson’s Disease, 
4.8% collagen vascular disorders, 4.1% intestinal pseudo obstruction and 6% miscellaneous (Soykan, 1998). The majority of  patients (up to 80%) with gastroparesis are women ( Parkman, 
2019).  
The symptoms of gastroparesis are nonspecific and may mimic other disorders such as functional 
dyspepsia. 
Treatment of symptomatic gastroparesis generally fo llow these principles ( Quigley, 2001):  
1. Dietary recommendations to correct fluid, electrolyte or nutritional deficiencies; 
2. Identify and rectify the underlying cause of gastroparesis, if possible; and  
3. Reduce the symptoms of gastroparesis.  
For diabetic patients with gastroparesis, improvement of glucose control has been shown to 
increase antral contractility, correct gastric dysrhythmias and accelerate gastric emptying 
although there have been no long- term studies confir ming the beneficial effects of maintaining 
euglycemia on gastroparetic symptoms ( Parkman, 2004).  
Treatments are based on the symptom presentation and usually include antiemetic agents or 
prokinetic agents. Currently the only treatment approved in the [LOCATION_002] ( US) for 
gastroparesis is metoclopramide (Prescribing information for Reglan, ANI Pharmaceuticals, Inc., Baudette, MN 2017; Prescribing information for Gimoti , Evoke Pharma, 2021) . The currently 
approved indication f or metoclopramide oral or nasal spray is relief of symptoms in adults with 
acute and recurrent diabetic gastroparesis  (DG) , although this medication has a black -box 
warning limiting treatment to no more than [ADDRESS_1030779]. Approximately 80% of 
the total body 5- HT is found in the gut where it plays a central role in the initiation of the 
peristaltic reflex on enteric neurons. Serotonergic drugs have been  developed for gastric motility 
disorders, but these products were not selective, e.g. c isapride and t egaserod were withdrawn 
from the market due to adverse events  (AEs). PCS12852 has a high binding affinity for the [ADDRESS_1030780] of PCS12852 on gastric 
motility, showing significant increases in the gastric emptying rate in rats, restoring gastric 
emptying in clonidine -induced gastroparesis in male beagle dogs and decreasing the gastric 
emptying time at all dose levels in cynomolgus monkeys.  
Cardiovascular effects were reported with earlier 5 -HT 4 agonists (prolonged QTc increasing risk 
for arrythmias) resulting in the withd rawal of these products from the market  possibly due to 
their off target effects . The safety pharmacology studies conducted with PCS12852 showed a low 
risk of any off -target effects on the cardiovascular, central  or respi[INVESTIGATOR_27441] . 
A previous study (S tudy 102) evaluated the single and multiple dose pharmacokinetics (PK) and 
pharmacodynamics (PD) in healthy patients  and in patients with functional constipation. 
Study 102 was a randomized, double -blind/open label, placebo/active controlled study . 
Prucalo pride was the active control included in the 102 study. An immediate release (IR) and a 
modified release formulation (DR) of PCS12852 were studied over the 0.[ADDRESS_1030781]. Systemic exposures following adm inistration of 
the IR formulation increased linearly over the 0.3 mg to 3 mg dose range. Steady state 
concentrations were achieved by [CONTACT_190758] 5, consistent with the half -life of 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     22 of 85    20 April 2022  approximately 24 hours. Only the IR formulation is currently being e valuated in the development 
of PCS12852.  
In terms of PD, PCS12852 resulted in pharmacologic activity related to stool assessments. There 
was a trend in improvement over placebo and comparable to prucalopride in terms of average 
weekly spontaneous bowel movements over the 2- week treatment period. PCS12852 was safe 
and generally well -tolerated with single and multiple doses under fasted and fed conditions in the 
healthy male and female patients  and in patients with functional constipation. 
In the 102 study, an exploratory evaluation was also perform ed to investigate the change from 
baseline in gastric emptying measured by [CONTACT_752897] 7 for the low dose -immediate 
release cohort (IRM) at 0.05  mg and 0.1 mg, as well as the delayed release multiple dose cohort 
(DRM) at the various doses between 0.5 t o 2 mg doses. The gastric emptying rate was estimated 
from the GEBT for each patient  over time (45, 90, 120, 150, 180, and 240 minutes). The Area 
Under the Curve ( AUC ) for gastric emptying for each patient  was determined as well as the 
change in the AUC fr om baseline for each patient . The time for 10% and 50% of the gastric 
emptying was also estimated from the GEBT. In the IRM cohort, the change from baseline in 
gastric emptying rate increased in both PCS12852 IR 0.[ADDRESS_1030782] 
(GEBT ), but less effect was noted with the 0.05 mg daily dose. Safety for multiple dosing up to 
3 mg daily has been well tolerated in the Phase 1 studies. This  Phase 2A study will evaluate the 
effects of PCS12852 at the 0.1 and 0.5 mg dose levels vs. placebo on gastric emptying rate after 28 days of treatme nt. The study will also evaluate the effects of PCS12852 treatment on the 
symptoms of gastroparesis assessed by [CONTACT_752898] -GCSI -DD scale.  
2.2 Background  
PCS12852 (formerly known as YH12852) was previously developed by [CONTACT_752899] (Korea) for the treatment of gastrointestinal motility disorders including chronic constipation, constipation- predominant irritable bowel syndrome, functional dyspepsia and gastroparesis. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030783] was acquired by [CONTACT_752900], Inc. (Processa) and is being 
further developed for the treatment of gastroparesis.  
Although there have been advances in understanding the mechanisms and pathophysiology of gastroparesis, there are still significant gaps in knowledge, inconsistencies across studies, and 
potential differe nces between different etiological groups (for example, diabetic versus 
idiopathic). Currently , the only FDA approved treatment for gastroparesis is metoclopramide. 
However, it carries a black box warning, as it is generally not well -tolerated and chronic use 
(>12 weeks) may lead to extrapyramidal side effects and potential irreversible tardive dyskinesia. 
Based on the limitations in currently available products for the treatment of gastroparesis, there still remains an unmet need for new treatments for the se patients.  
In support of the clinical development program for PCS12852, in vitro,  ex vivo  and in vivo  
pharmacology, safety pharmacology, pharmacokinetic and toxicology studies have been conducted. PCS12852 has been shown to have a high binding affinity for the 5- HT
4 receptor 
with more than 200- fold selectivity over other 5 -HT receptors, as well as for 80 targets including 
receptors, ion channels and transporters. PCS12852 also exhibits 3.4 times more potent agonistic activity than tegaserod to human 5- HT
4A receptors stably expressed in Chinese hamster ovaries 
(CHO) . In studies of ex vivo  contractile activi ty in guinea pig colon, PCS12852 was found to be 
[ADDRESS_1030784] were evaluated in various 
models including rat, dog and monkey. Single oral administration of PCS12852 at dose s of 3 to 
10 mg/kg in rats significantly increased the gastric emptying rate and PCS12852 at 3 mg/kg 
showed a comparable effect to that of another selective [ADDRESS_1030785], mosapride at 10 mg/kg. In 
rat models of delayed gastric emptying and feeding inhibit ion induced by [CONTACT_752901], single 
oral administration of PCS12852 at doses of 1, 2 and 3 mg/kg dose -dependently improved 
gastric emptying, and doses of 1 and 2 mg/kg led to significant restoration of food intake. Single 
oral administration of PCS12852 at 1.0 μ g/kg, significantly restored gastric emptying up to 
normal levels under conditions of clonidine -induced delayed gastric emptying in conscious 
beagle dogs. Single oral administration of PCS12852 at doses of 0.2, 0.4 and 1 mg/kg also 
significantly shortened the gastric emptying time as measured by [CONTACT_5203] -time fluoroscopy imaging 
in monkeys. In addition to the efficacy shown in the gastroparesis models, PCS12852 significantly increased fecal pellet output at 0.1, 0.3, 1, 3 and 10 mg/kg in male guinea pi[INVESTIGATOR_752877] 3, 10 and 30 
μg/kg and significantly increased giant migrating contraction frequency at 30 μ g/kg in female 
dogs. These data demonstrate that PCS12852 possesses exc ellent prokinetic effects in the upper 
and lower GI tracts.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     24 of 85    20 April 2022  In cardiovascular safety studies, PCS12852 decreased hERG K+ currents in a dose -dependent 
manner, with an IC 50 value of 0.71 μ M in CHO cells and increased action potential duration 
(APD) at concen trations of 4.52 μ M in isolated rabbit Purkinje fibers. Considering the affinity of 
PCS12852 for the human 5- HT 4A receptor (IC 50, 0.05 nM) and the expected C max at doses up to 
10 mg in human subjects, (free -drug C max = 2.89 nM, total -drug C max = 72.26 nM), it is estimated 
that there is little risk of hERG inhibition, action potential duration (APD) prolongation or 
cardiovascular contractility exists at the projected therapeutic clinical dose levels. In a telemetry 
study conducted with conscious  monkeys, there were no abnormal electrocardiograms  (ECG), 
blood pressure or heart rate findings after administration of single oral doses up to 60 mg/kg. In addition, no abnormalities were detected in ECG findings in 4- week and 13 -week repeat -dose 
oral to xicity studies in monkeys treated with doses up to 60 mg/kg/day. Additionally, in a 
telemetry study performed in conscious dogs, there were no abnormal changes in heart rate or ECG parameters after single intravenous administration up to 1 mg/kg. Additiona l safety 
pharmacology studies did not show any significant effects on neurobehavioral function or 
respi[INVESTIGATOR_4806]. 
Non-clinical toxicology studies of PCS12852 conducted so far include single -dose (rats and 
monkeys) and repeat -dose (rats and monkeys up to 13 weeks) toxicity studies, as well as in 
vitro/in vivo  genetic toxicology studies, carcinogenicity studies, developmental and reproductive 
studies. In the 13- week toxicology study in rats there were no treatment -related findings up to 
100 mg/kg/day. T he No Observable Adverse Effect Level (NOAEL) was determined to be 
100 mg/kg/day for both sexes. A 13- week repeat -dose oral toxicity study in monkeys, 
demonstrated treatment- related clinical signs including vomiting and soft/watery feces with 
increased neu trophil counts in both sexes at 60 mg/kg/day. Based on these findings, the NOAEL 
was determined to be 60  mg/kg/day for both sexes. No evidence for genotoxicity has been 
observed for PCS12852. In the carcinogenicity studies in rats and mice, no PCS12852- related 
neoplasms were noted. In fertility and early embryonic developmental toxicology studies in rats, 
there were no abnormal outcomes of mating, fertility or pregnancy. In addition, in embryo–fetal development studies in rats and rabbits, there has been no evidence suggesting that PCS12852 is dysmorphogenic.  
Two clinical phase 1 studies that include pharmacokinetic (PK) and pharmacodynamic (PD) information for PCS12852 have been conducted in healthy volunteers and patients. The first study, Study 101 was a randomized, double -blind, placebo/active -controlled, single/multiple 
dose Phase [ADDRESS_1030786] of food was evaluated over the 0.5  mg to 3 mg single dose range. The systemic 
exposure for PCS12852 increased in a dose -proportional manner following single and multiple 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     25 of 85    20 April 2022  administrations under fed conditions; although peak exposure was increased in a slightly greater 
than dose -proportional manner at multiple doses of 0.5 to 3 mg. Food intake decreased 
PCS12852 C max by 75% and AUC (0-τ) by 61%, and delayed T max from 1.[ADDRESS_1030787] onset of spontaneous bowel movements following single and multiple doses. 
A second study, Study 102, evaluated the single and multiple dose PK and PD in healthy patients  
and in patients with functional constipation. This was a randomized, double -blind/open label, 
placebo/active controlled study. Prucalopride was the active control. An immediate release (IR) 
and a delayed release formulation (DR) of PCS12852 were studied over the 0.[ADDRESS_1030788]. Systemic exposures following administration of 
the IR formulation increased linearly over the 0.3 mg to 3 mg dose range. Steady state 
concentrations were achieved by [CONTACT_190758] 5, consistent with the half -life of 
approximately 24 hour s. In the groups that evaluated the modified release formulation (DR), a 
delay in T
max for PCS12852 was noted, as expected. In terms of PD, PCS12852 resulted in 
pharmacologic activity related to stool a ssessments. There was a trend in improvement over 
placebo and comparable to prucalopride in terms of average weekly spontaneous bowel movements over the 2- week treatment period. PCS12852 was safe and generally well -tolerated 
with single and multiple doses under fasted and fed conditions in the healthy male and female patients  and in patients with functional constipation. 
In the 102 study, an exploratory evaluation was also performed to investigate the change from 
baseline in gastric emptying measured by [CONTACT_752902] T on Day 7 (for the low dose -immediate release 
cohort (IRM) and the delayed release multiple dose cohort (DRM) only). The time for 10% and 
50% gastric emptying was analyzed, along with the area under the curve ( AUC ) of the 
13C rate 
measured in breaths and the analysis of the gastric emptying rate over time (45, 90, 120, 150, 180, and 240 minutes). In the IRM cohort, the change from baseline in gastric emptying rate 
increased in both PCS12852 IR 0.1 mg and 0.05 mg groups. Additionally, the AUC of the 
13C 
rate showed a statistically significant change from baseline in the PCS12852 IR 0.1 mg group. 
Similar results were noted for DRM cohort.  
All doses of PCS12852 in both of the clinical studies were well tolerated and no serious adverse events (SAEs) occurred. T he most frequent treatment -emergent adverse events were diarrhea, 
headache, and nausea. There were no changes in vital signs, platelet aggregation or ECG parameters including no sign of QTc prolongation in time -matched ECGs monitored in the single 
ascendin g dose cohort.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     26 of 85    20 April 2022  The non- clinical and limited clinical safety and efficacy data accumulated thus far support 
further investigation on the efficacy, safety and tolerability of multiple doses of PCS12852 IR 
formulation for the treatment of gastroparesis. 
2.3 Benef it/Risk Assessment  
The clinical benefit/risk profiles of these [ADDRESS_1030789] been complicated by [CONTACT_752903] t o unintended target receptors or channels. For 
example, the marketing of both cisapride and tegaserod was discontinued due to cardiovascular 
concerns (cardiac arrhythmias with cisapride and ischemic events with tegaserod, respectively). Tegaserod, which is  used for the treatment of  irritable bowel syndrome -constipation and chronic 
constipation, was also found to be an agonist for the 5- HT
1B and 5- HT 1D receptors, as well as an 
antagonist for 5- HT 2B receptors. This nonselectivity may explain its association w ith rare, but 
serious, instances of ischemic AEs, including stroke and angina. Therefore, more highly selective 
5-HT 4 receptor agonists are expected to exhibit favorable safety profiles with a lower risk of 
cardiovascular side effects  ( Manabe, 2010; FDA Briefing Document, 2011) . Prucalopride, a 
recently developed selective [ADDRESS_1030790], is intended to be used by [CONTACT_752904]-responders  (NICE, 2010) . However, it has been found that in several clinical trials, the most 
common reason for discontinuation of prucalopride medication was its poor response  rate 
(Movetis, 2008 [PRU -[LOCATION_003] -22]; Movetis, 2008 [PRU -INT-17]; Movetis, 2008 [PRU -INT-10]). 
This implies that a significant number of refractory patients still exist. In addition, recently -
developed IBS and chronic constipation drugs such as linaclotide ar e considered expensive 
compared to traditional laxatives. Linaclotide at 1,[ADDRESS_1030791] on upper 
gastrointestinal motility, as measured by [CONTACT_752905].  
A series of in vitro  and in vivo  safety pharmacology studies were conducted to assess PCS12852 
for evidence of off -target receptor binding and adverse effects on the central nervous, 
cardiovascular and respi[INVESTIGATOR_27441] . Exposure multiples were estimated based on the human 
Cmax (free -drug C max = 2.89 nM , total -drug C max 72.26 nM) at the highest dose of 10 mg in the 
SAD study.  PCS12852 decreased hERG K+ current in a dose -dependent manner with an IC 50 
value of 710 nM, obtained using the whole -cell patch clamp technique to measure peak hERG 
tail current in CHO cells (G12070). An isolated rabbit Purkinje fiber assay (G12171), revealed 
that PCS12852 increased APD  at a concentration of 4.52 μ M. Ex vivo  contractility testing using 
tissue chambers with isolated rat aorta and canine coronary artery demonstrated th at PCS12852 
did not significantly influence canine coronary artery or aorta isometric tone in sham -operated or 
DOCA- salt hypertensive rats at concentrations of 0.1 to 100 μ M. Considering the affinity of 
PCS12852 for the human 5- HT 4A receptor (IC 50, 0.05 nM ) and C max (free -drug C max = 2.89 nM, 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     27 of 85    20 April 2022  total- drug C max = 72.26 nM) at 10  mg in the SAD study, it is estimated that little or no risk of 
hERG inhibition, APD prolongation or cardiovascular contractility exists at the projected 
therapeutic clinical dose level s. 
In summary, PCS12852 at the doses of 3 and 10 mg/kg significantly increased solid gastric 
emptying rates in rats, and its effect appears to be comparable to that of mosapride, indicating 
that PCS12852 may accelerate gastric emptying in patients with gas troparesis or functional 
dyspepsia. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs associated with PCS12852 are provided in the I nvestigator’s B rochure.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     28 of 85    20 April 2022  3 Objectives  and Endpoints  
Table 2  Objectives  and Endpoints  
Objectives Endpoints  
Primary   
• To evaluate the effect of different doses of 
PCS12852 on the gastric emptying rate, as 
measured by [CONTACT_145425], in patients with 
moderate to severe idiopathic gastroparesis 
(IG) or  DG 
• To evaluate the PK profile of PCS12852 at 
different dose levels.  
 • Change in gastric emptying rate from baseline 
as determined by [CONTACT_752906] 6 (Day 28) after administration 
of the PCS12852 or placebo. 
• Change in gastric emptying rate from baseline 
using the t 10 and t 50 metric for gastric 
emptying rate.  
• Concentrations of PCS12852 in plasma; PK 
parameters will be estimated from concentration -time data using 
noncompartmental methods, as data permit.  
 
Secondary   
• To evaluate the effect s of different doses of 
PCS12852 on symptoms, as measured by [CONTACT_752907] (ANMS 
GCSI -DD), in  patients with moderate to 
severe idiopathic and diab etic gastroparesis  • Change from baseline in the ANMS 
GCSI -DD) ( i.e., Day -7 to Day -1) (predose) 
and Day 7 (Day 1 to Day 7)  
• Change from baseline in the ANMS 
GCSI -DD ( i.e., Day -7 to Day - 1) (predose) 
and Day 14 (Day 8 to Day 14)  
• Change from baseline in the AN MS 
GCSI -DD ( i.e., Day -7 to Day - 1) (predose) 
and Day 21 (Day 15 to Day 21)  
• Change from baseline in the ANMS 
GCSI -DD ( i.e., Day -7 to Day - 1) (predose) 
and Day 28 (Day 22 to Day 28)  
Exploratory Efficacy  
• To evaluate the effects of different doses of 
PCS12852 on symptoms  or QOL , as 
measured by [CONTACT_752908] -SYM, PAGI -QOL, 
PGI-S, PGI -C, CGI -S and CGI -I, in patients 
with moderate to severe idiopathic or diabetic 
gastroparesis  • Change from baseline in ANMS GCSI -DD 
score over time (Day 7, 14, 21, 28) by 
[CONTACT_508203] 7 to Day 14, Day 14 to 
Day 21 and Day 21 to Day 28. 
• Change from baseline in the sub scores (nausea, early satiety, postprandial 
fullness, upper abdominal pain and 
number of vomiting epi[INVESTIGATOR_1841]) of the 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     29 of 85    20 April 2022  Objectives Endpoints  
 ANMS -GCSI -DD over time (Day 7, 14,  
21, 28) by [CONTACT_508203] 7 to Day  14, 
Day 14 to  Day 21 and  Day 21 to  Day 
28. 
• Change from baseline in PAGI -SYM and 
PAGI -QOL scores over time by [CONTACT_752892] 1 to Day 28.  
• Change from baseline in Clinical Global 
Impression -Severity ( CGI-S) and Clinical 
Global Impression- Improvement ( CGI-I) 
scores over time by [CONTACT_508203] 1 to 
Day 28.  
• Change from baseline in PGI -S and PGI -C 
scores over time by [CONTACT_508203] 1 to 
Day 28. 
Safety  
To evaluate the safety and tolerability of different doses of PCS12852 in idiopathic and diabetic 
gastroparesis patients.  • Adverse Events (by [CONTACT_24975], severity, and 
relatedness) at each visit.  
• Changes in safety clinical laboratory testing 
and vital signs at each site visit.  
• Changes in ECGs at each site visit  and the 
potential correlation of the PK with changes 
in the ECG . 
• Change from baseline in the C-SSRS scores 
over time by [CONTACT_508203] [ADDRESS_1030792] successfully completed Screening criteria (Visit 1) 
will return for a second Screening Visit (Visit 2) where the inclusion/exclusion criteria will be 
re-evaluated.  
Visit 1 will include all safety labs and procedures (including an ECG) as well as the Columbia -Suicide Severity Rating Scales  (C-SSRS) assessed by [CONTACT_752909]. If  patients  still meet study criteria 
when returning for Visit 2, a GEBT will be performed and the patient  will be educated on 
completion of the ANMS GCSI -DD. Patients will complete the ANMS GCSI -DD for [ADDRESS_1030793] 
overnight (at least 8 hours) prior to coming to the site for the test. The patient will have their 
glucose tested both before and after the GEBT. The patient must have a fasting blood glucose of 
≤275 mg/dL  to proceed with the GEBT. If the patient does not have a FBG ≤ 275 mg/dL, they 
are permitted to come in the following day to perform the GEBT test . If the patient’s FBG is not 
within range at Visit 6, the patient will be sent home with an additional dose of study medication 
and asked to return the next day to perform the GEBT .  
Patients will return to the site for Day 1 ( Visit 3 [ Randomization] ) where patients who meet the 
criteria for having moderate to severe symptoms based on the ANMS GCSI -DD will be 
randomized in a 1:1:1 ratio into three treatment groups, PCS12852 0.1 mg, PCS12852 0.5 mg or placebo. At Visit  3, patients will answer a series of questionnaires  including the Patient 
Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI -SYM), Patient 
Assessment of Upper Gastrointestinal Disorders – Quality of Life (PAGI -QOL), Patient Global 
Impression of Severity (PGI -S) and the Patient Global Impression of Chan ge (PGI -C). Patients 
will arrive in a fast ed condition and have PK samples drawn prior to receiving the first dose and 
at the following times after the first dose, 0.5, 1, 2, 4, 6, and 8 hours. The ECG should be performed prior to the 4- hour PK draw betwee n the 2 - and 4- hour samples. The investigator will 
assess the patient through the C -SSRS as well as the CGI -S and CGI -I. 
Patients will return to the site on Day 7 (Visit 4) and Day 14 (Visit 5) to undergo safety and 
tolerability assessments  as per the Schedule of Assessments,  along with the investigator 
assessing the patient for the C -SSRS to ensure the patient does not have any suicidal tendencies 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     31 of 85    20 April 2022  or ideation.  Sites will be asked to schedule the patient’s visit so that the ECG can be performed 
approximate ly 4 hours after the patient’s dose.  
Patients will take their assigned treatment once daily for 28 days and will return to the site on Day 28 (Visit 6)  for their final dose . On Visit 6, PK  samples will be  drawn and the GEBT will be  
repeated. During the tr eatment period , the patients will also complete the ANMS GCSI -DD. 
Each patient will be told to take one tablet from their assigned kit each day at approximately the 
same time each morning, at least 30 minutes prior to a meal (actual dosing times will be captured via a dosing diary), while fasting starting on Day 1  for 28 days.  
On the morning of Day 28 , after fasting overnight  (for at least 8 hours ), the patient will return to 
the site for Visit 6. At Visit 6, the patient will again compete the patient assessments  and will 
have a PK sample drawn prior to receiv ing the  final dose of PCS12852 or placebo and then have 
PK samples drawn at 0.5, 1, 2, 4, 6, and [ADDRESS_1030794] a fasting blood 
glucose (FBG) of ≤275 mg/dL  to proceed with the GEBT.  If the patient’s FBG is not within 
range, the patient will be sent home with an additional dose of study drug and asked to return the next day to perform the GEBT  and P K sampling . The GEBT test will be performed for 4 hours  
and will be administered approximately 30- 60 minutes after the patient’s final dose of study 
treatment . During the GEBT test, the site will prioritize taking the GEBT samples and then the 
PK samples. After the test is complete the patients will be discharged and then will return approximately 48- 72 hours after Day 28 (Visit 6) to ha ve a PK blood sample drawn. The patient 
will also return to the site  1 week after the Day 28 visit  for a follow -up visit  (Day 35/Visit 8 ). 
The total study duration for each patient  is expected to be approximately 8 weeks  (3 weeks for 
Screening , 4 weeks for treatment, and 1 week for follow -up). 
The SoA displaying assessments/tasks and time points is presented in Table 1 . 
 
4.2 Scientific Rationale f or Study Design  
This study has been designed to comply with recommendations  in the FDA Guidance: 
Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry. 
Several design features have been incorporated in the study in an effort to minimize bias, 
including double -blind design and random assignment of patients , helpi[INVESTIGATOR_752878]. The use of a 
placebo control permits prospective comparison between the PCS [ADDRESS_1030795] appeared to be safe and generally 
well-tolerated after both single (0.5 to 10 mg) and multiple doses (0.05 to 3 mg QD) 
(Section  2.1). The most frequently reported AE was headache. All AEs were generally mild and 
resolved without treatment. Therefore, t he doses to be administered in the proposed Phase 2A 
study are 0.[ADDRESS_1030796] completed the study if he/she has completed all [ADDRESS_1030797] visit (Visit 8) . 
Independent of the end of study definition, all laboratory tests with values considered clinically 
significantly abnormal  during participation in the study or within [ADDRESS_1030798] dose of 
study treatment should be  repeated until the values return to normal or baseline or are no longer 
considered clinically  significant by [CONTACT_752910].  
The overall stu dy will be stopped if ≥ 2 patients develop the same Grade 3 CTCAE (Common 
Terminology Criteria for Adverse Events) cardiac event or 1 patient develops a CTCAE ≥  Grade 
[ADDRESS_1030799] be able to provide written consent and meet all the inclusion criteria and none 
of the exclusion criteria based on S creening.  
5.1 Inclusion Criteria  
Patients  are eligible to be included in the study only if all of the following criteria apply:  
1. Has a documented diagnosis of moderate to severe DG or IG  according to the 
ANMS GCSI -DD score during the Screening period (Score of >2 o n average of 
the screening days) . 
2. Moderate to severe delay in gastric emptying rate as measured by [CONTACT_752911] -time (t1/2) ≥ the 80th percentile of normative data as 
determined by [CONTACT_752888] . 
3. Male or female patients 18 to 80 years of age, inclusive, at baseline.  
4. Has continuous moderate to severe symptoms for gastroparesis  (that is, chronic 
postprandial fullness, abdominal pain, postprandial nausea, vomiting, loss of 
appetite and/or early satiety) as assessed by [CONTACT_752889] 3 
months. 
5. Has hemoglobin A1c (H bA1c) less than (<) 1 1 percent (%) . 
6. Has B ody M ass Index range between [ADDRESS_1030800] use one of the following acceptable 
methods of contraception throughout the study ([ADDRESS_1030801] dose of study medication) : oral contraceptive 
medication, intrauterine device (IUD), hormonal implants, injectable contraceptive medications, double -barrier methods, or tubal ligation. 
9. Females who are postmenopausal (age -related amenorrhea ≥ 12 consecutive 
months and increased follicle -stimulating hormone [FSH] > 40 mIU/mL. If 
necessary, to confirm postmenopausal status, an FSH will be drawn at Screening) or who have undergone hysterectomy or bilateral oophorectomy are exempt from 
pregnancy testing. 
10. Male patients must be willing to use acceptable contraceptive measures such as 
vasectomy or double barrier method and refrain from sexual activity with any 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     34 of 85    20 April 2022  female who is pregnant or lactating .  Female partner s of study participants are 
asked to use acceptable methods of contraception as listed in Inclusion #[ADDRESS_1030802] be willing and able to comply with study procedures.  
13. Compliance with the completion of the ANMS GCSI -DD, defined as 
approximately 80% diary completions, during the screening period. For those 
patients whose compliance is measured to be <80%, the final decision to randomize a patient will be made by [CONTACT_2725] (or designee).  
14. Patient must be willing and able to provide signed, informed consent.  
5.2 Exclusion Criteria  
Patients  are excluded from the study if any of the following criteria apply:  
1. Has acute, severe gastroenteritis and pronounced dehydration in the past 48 hours 
prior to Screening, chronic parenteral feeding or persistent severe vomiting. 
2. Has known hypersensitivity to Spi[INVESTIGATOR_112174], egg, milk products or wheat allergens.  
3. Has a known disturbance of  small intestinal absorption, exocrine pancreatic 
function, liver metabolism or  pulmonary function. 
4. Has a history of anorexia nervosa or bulimia.  
5. Previous history of bezoars (the presence of retained liquid, bile, or small amounts of poorly organized food residue is permitted).  
6. Prior surgery involving any gastrointestinal surgery, including the luminal gastrointestinal (GI) tract (cholecystectomy  and appendectomy are permitted if 
performed greater than (>) 3 months prior to baseline GEBT). 
7. Any abdominal or pelvic surgery within the past 3 months. 
8. Known or history of the following GI conditions: inflammatory bowel disease; irritable bowel syndrome with diarrhea;  or any other active disorder that could 
explain symptoms in the opi[INVESTIGATOR_871] . 
9. Has active diverticulitis, diverticular stricture, and other intestinal strictures.  
10. Has feeding or decompression tubes and/or a gastric pacemaker.  
11. Has had Botox pyloric injections within the prior 3 months . 
12. Has had diabetic ketoacidosis (within the prior 4 weeks).  
13. Currently taking Glucagon- like peptide -1 (GLP -1) agonists , e.g. exenatide, 
liraglutide, semaglutide or dulaglutide , or pramlintide.  
14. Has severe psychiatric illness (including suicidal tendencies or ideation) or neurological illness. 
15. History or suspi[INVESTIGATOR_752876], barbiturate, amphetamine or narcotic abuse.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     35 of 85    20 April 2022  16. Use of narcotics/opi[INVESTIGATOR_2438], drugs used to treat gastroparesis within [ADDRESS_1030803].  
17. Anticipated concurrent use of a strong Cytochrome P450 ( CYP ) inhibiting or 
inducing drug (listed in Section 6.7.1) that would significantly alter the metabolism of PCS12852 and/or its metabolites during the course of the study (after Screening)  
18. Fever (> 38°C), or chronic, persistent, or recurring infection(s) at Screening or 
baseline.  
19. Clinically significant cardiac disease including but not limited to unstable angina, 
acute myocardial infarction within 6 months of baseline, and arrhythmia requiring therapy.  
20. Patient has QTcF  interval ≥ 480 milliseconds on Screening ECG; a second 
Screening ECG may be done at the I nvestigator’s discretion but the average of the 
two QTc F screening intervals must not be ≥ 480 milliseconds. 
21. History of cerebral hemorrhage, cerebrovascular accident, transient ischemic attack, gastrointestinal bleeding, or retinal hemorrhage within 6 months of 
baseline.  
22. Patient has active or history of neoplas tic disease (except for adequately treated 
non-invasive basal cell and/or squamous cell carcinoma of the skin or carcinoma 
in situ of the cervix) within the past 5 years prior to baseline.  
23. Presence of clinically significant medical condition(s) including b ut not limited 
to: renal, hepatic, cardiovascular, hematological, gastrointestinal, endocrine, 
pulmonary, neurological, psychiatric, substance abuse, and/or any other clinically significant disease or disorder, which in the opi[INVESTIGATOR_689] (by [CONTACT_752912]), may put the patient at risk due to 
participation in the study, influence the results of the study, and/or affect the patient’s ability to complete the study.  
24. History of or current diagnosis of active tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by [CONTACT_53803] [ADDRESS_1030804] with purified protein derivative with induration >  = [ADDRESS_1030805] or positive or borderline T -SPOT [Elispot] test); or positive TB test at 
Screening. Patients with documented completion of appropriate LTBI treatment would not be excluded and are not required to be tested. 
25. Vaccination with live or live -attenuated virus vaccine within 1 month prior to 
baseline.  Vaccines for COVID -19 are allowed.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     36 of 85    20 April 2022  26. The results of the following laboratory tests performed at the central laboratory at 
Screening meet any of the criteria below:  
a. Hemog lobin < 8.0 g/dL (International System of Units: < 80 g/L)  
b. White blood cells < 3.0 x 10^3 cells/mm^3 (SI: < 3.0 x 10^9 cells/L)  
c. Neutrophils < 1.0 x 10^3 cells/mm^3 (SI: < 1.0 x 10^9 cells/L)  
d. Lymphocytes < 0.5 x 10^3 cells/mm^3 (SI: < 0.5 x 10^9 cells/L)  
e. Platelets < 100 x 10^3 cells/mm^3 (SI: < 100 x 10^9 cells/L)  
f. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
and/or alkaline phosphatase (ALP) ≥ 2 x upper limit of normal (ULN)  
g. Total bilirubin level ≥ [ADDRESS_1030806] unless the individual has been diagnosed with Gilbert’ s disease and this is clearly documented  
h. Estimated glomerular filtration rate < 40 mL/min/1.73 m^2 based on the Modification of Diet in Renal Disease formula  
i. Creatinine ≥ 3 mg/dL  
j. Positive human immunodeficiency virus serology  
k. Evidenc e of active Hepatitis B Virus infection  
l. Evidence of active Hepatitis C Virus infection  
27. Women who are pregnant or breastfeeding.  
28. Any other medical condition, serious intercurrent illness, or extenuating 
circumstance that, in the opi[INVESTIGATOR_689], would preclude participation in the study.  
29. Use of any investigational product within [ADDRESS_1030807] of the study. T here are no other specific lifestyle restrictions in the study. 
5.3.1 Meals and Dietary Restrictions 
Please refer to Section 4.1 for details regarding the standardized low calorie meal  that the 
patients will consume at Visits 2 and 6 . Please refer to the SoA ( Table 1 ) for timing of the GEBT.  
5.4 Screen Failures 
Screen failures are defined as patients who consent to participate in the clinical study but are not subsequently enrolled in the study. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     37 of 85    20 April 2022  Individuals who do not meet certain criteria (e.g. lab values) for participation in this study 
(screen failure) may be rescreened.  The GEBT test will not be repeated on a patient that does not 
meet GEBT entry criteria.  
[ADDRESS_1030808] ered 
Study Treatment  PCS12852  Placebo  
Dosage Formulation  Tablet  Tablet  
Unit Dose Strengths  0.1 mg and 0.5 mg  N/A  
Route of Administration  Oral Oral 
Packaging and Labeling  
PCS12852 tablets and matching placebo tablets will be packaged in high density polyethylene 
bottles respectively.   
Each patient’s study medication will be packaged in a study- specific box (kit) and shipped to the 
study site by a central distribution site.  
 
Treatment Schedule  
Regardless of the patient’s assigned treatment group, e ach patient will take one tablet from their 
assigned kit at approximately the same time each  morning and at least  [ADDRESS_1030809] be stored in the 
original packaging between 20 to 25°  C (68  to 77 ° F), with deviations permitted between 15 to 
30°C (59 to  86° F) and protected from extreme conditions of temperature, light, and humidity.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030810] be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance  with the 
labeled storage conditions with access limited to the Investigator and authorized site staff.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance ( e.g., 
receipt, reconciliation, and final disposition records). 
Further guidance and information for the final disposition of unused study treatment  are provided 
in the Study Reference Manual.  
6.3 Measures to Minimize Bias: Randomization and Blinding  
Patients who have successfully completed Screening criteria (Visit 1  and Visit 2 ) will return for a 
Randomization visit (Visit 3) where the inclusion/exclusion criteria will be evaluated and 
patients who meet the criteria will be  randomized in a 1:1 :1 ratio into  one of the three  treatment 
groups, PCS12852 0.1mg, PCS [ZIP_CODE] 0.5mg  or placebo  via Interactive Response Technology 
(IRT) .  The planned sample size to be randomized is 24 patients . The randomization to treatment 
groups will be stratified by [CONTACT_24975] ( IG, DG ), enrolling at least [ADDRESS_1030811] of treatment allocations will be kept in a secure location by [CONTACT_752913] .  Access to the t reatment allocations will be monitored 
by [CONTACT_752914]/Quality Assurance; any access to the allocations prior to unblinding the study will be documented by [CONTACT_752914]/Quality Assurance and included in the Clinical 
Study Report.   
Table 4  Measures to Minimize Bias  
Study using IRT  All patients  will be centrally randomized using an Interactive Response 
Technology (IRT) . Each patient will be assigned a unique number 
(randomization number) that encodes the patient’s assignment to one of the 3 
arms of the study, according to the randomization schedule using a validated 
computer program. Details of the procedure are described in the IRT M anual 
provided to all sites.  
Study treatment will be administered/dispensed at the study visits  as summarized 
in the SoA ( Table 1 ). 
Returned study treatment  should not be re -dispensed to the patients . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     39 of 85    20 April 2022  Blind b reak ( IRT) This is a double -blind study in which patients  are blinded to study treatment . 
The IRT  will be programmed with blind- breaking instructions. In case of an 
emergency, the Investigator has the sole responsibility for determining if 
unblinding of a patient’s  study treatment assignment is warranted. Patient  safety 
must always be the first consid eration in making such a determination. If the 
Investigator decides that unblinding is warranted, the Investigator should make 
every effort to contact [CONTACT_752915] a patient’s  study  
treatment assignment unless this could delay em ergency treatment for the 
patient . If a patient’s  study treatment assignment is unblinded, the Sponsor  must 
be notified within [ADDRESS_1030812] be recorded. 
 
The Sponsor  may unblind the treatment assignment for any patient  with an SAE. If the SAE 
requires that an expedited regulatory report be sent to one or more regulatory agencies, a copy of 
the report, identifying the patient’s  treatment assignment, may be sent to Investigators in 
accordance with local regulations and/or S ponsor policy. 
6.4 Study Treatment  Compliance  
When patients  are dosed at the site, study treatment will be administered directly by [CONTACT_25309]. All dosing by [CONTACT_752916]’s dosing diary. The date and time of each dose administered in the 
clinic will be recorded in the source documents. The dose of study treatment and study patient  
identification will be confirmed at the time of dosing by a member of the study site staff other than the person administering the study treatment . 
For self-administration of the  study treatment  at home  by [CONTACT_102] , compliance with study 
treatment  will be assessed at each visit. Compliance will be assessed by [CONTACT_752917] . Deviations from the prescribed dosage regimen should be recorded. Fi nal drug 
accountability will be done by [CONTACT_752918]’s final visit.  
A record of the quantity of study treatment  dispensed to and administered  by [CONTACT_752919]. Treatment  start and 
stop dates, including dates for treatment delays and/or dose reductions will also be recorded.  
6.5 Continued Access to Study Treatment  After the End of the Study  
The study treatment  will not be available to the patients at the end of the study. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     40 of 85    20 April 2022  6.6 Treatment of Overdose  
For this study, any dose of study treatment  greater than 20 tablets within a 24- hour time period 
will be considered an overdose.  
In the event of an overdose, the Investigator should:  
• Contact [CONTACT_10990].  
• Evaluate the patient  to determine, in consultation with the medical monitor , whether study 
treatment should be interrupted or whether the dose should be reduced.  
• Closely monitor the patient  for any AE /SAE and laboratory abnormalities until study 
treatment  can no longer be detected systemically . 
6.7 Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, recreational 
drugs, vitamins, and/or herbal supplements)  that the patient  is receiving at the time of enrollment 
or receives during the study must be recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency  
As much as possible, the dose and frequency of all concomitant medications  taken for chronic 
conditions except for diabetes mellitu s (see Section 6.7.2)  should be held stable during the study. 
The Medical Monitor  should be contact[CONTACT_63193].  
6.7.[ADDRESS_1030813] GI motility, either  positively or 
negatively, and therefore could confound the assessment of the efficacy of the study tr eatment  on 
the signs and symptoms of gastroparesis. 
Prohibited concomitant treatment includes cannabis, opi[INVESTIGATOR_2438] , GLP -1 agonists (e.g. exenatide, 
liraglutide, semaglutide or dulaglutide, or pramlintide), cisapride, tegaserod, prucalopride, 
metoclopramide, bethanechol, domperidone and erythromycin or any other medications that are contraindicated for patients with gastroparesis . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     41 of 85    20 April 2022  IMPORTANT:  Patients should be instructed to consult with the Investigator before taking 
any new medication or changing medications and/or dosing regimens throughout the study.   
Drugs that are known to be strong inhibitors or inducers of Cytochrome P450 ( CYP ) (most likely 
CYP3A4 and CYP1A2) may significantly alter exposure to the investigational product , and as 
such, are strictly prohibited while on the study.    Examples of  CYP  inhibitors include 
cimetidine, ciprofloxacin, fluvoxamine, clarithromycin, dil tiazem, grapefruit juice, and 
itraconazole. E xamples o f CYP i nducers include carbamazepi[INVESTIGATOR_050], phenobarbital, tobacco, and St. 
John’s wort.  
P-glycoprotein ( P-gp), breast cancer resistance protein (BCRP), and gastric acid 
reducing agents may also significantl y alter the exposure of the investigational 
product and as such,  are strictly prohibited while on study.  Examples of P -gp 
inhibitors  include  cyclosporine, amiodarone, and itraconazole as well as BCRP inhibitors 
include novobiocin, sulfasalazine and cyclosporine A which may potentially increase the 
systemic exposure. Examples of P -gp inducers include carbamazepi[INVESTIGATOR_050], phenytoin and 
rifampin.  Examples of BCRP inducers and gastric acid reducing agents include 
venlafaxine, apalutamide and dovitinib as well as PPI s (esomeprazole, lansoprazole, 
omeprazole, etc), H2 blockers (ranitidine, famotidine, nizatidine) which may potentially 
decrease the systemic exposure.  
 
6.7.2 Permitted Treatments  
Any medication or vaccine (including over -the-counter  or prescription medicines, vitamins, 
and/or herbal supplements) that the patient  is receiving at the time of enrollment or receives 
during the study must be recorded in the eCRF along with:  
• indication  
• dates of administration including start and end da tes 
• dosage information including dose and frequency  
 
Diabetic gastroparesis patients enrolled in the study will likely consist mostly of patients 
receiving one or more prescription medications for blood- glucose control. Good clinical practice 
allows for frequent adjustment of medication by [CONTACT_752920], and this practice is encouraged in this study.  
It should be remembered that certain diabetic drugs (see Section 6.7.1) delay gastric emptying 
and are prohibited during this study. Other therapy considered necessary for the patient’s welfare 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     42 of 85    20 April 2022  may be given at the discretion of the Investigator. If the permissibility of a specific 
medication/treatment is in question, please contact [CONTACT_211410] . 
The Medical Monitor  or designee should be contacte d if there are any questions regarding 
concomitant or prior therapy. 
6.7.[ADDRESS_1030814] efficacy evaluations is strongly discouraged at any time after 
Visit 1 in the study. However, patients  who experience severe symptoms of gastroparesis  after 
entering the Treatment Period may receive a single day of treatment per week with an 
anti-emetic drug , but should avoid such treatment, if possible, on the day prior to and day of 
treatment visits. If a patient  requires an anti -emetic drug ( e.g., 5- HT 3 receptor antagonists, NK1 
receptor antagonists) for more than 1 day a week, or requires an antiemetic drug once weekly repeatedly ( i.e., more than 2 weeks while on study ), the Investigator should contact [CONTACT_752921].  
The following rescue medications may be used:  
• ondansetron or promethazine (tablet , syrup or suppositories) for emesis  
• loperamide for diarrhea  
• Tramadol for pain  
 
 
The date and  time of rescue medication administration as well as the name [CONTACT_752945].  
 
7 Discontinuation /Withdrawal Criteria 
It may be necessary for a patient  to permanently discontinue study treatment. Reasons for 
discontinuation from study treatment and/or the study may include the following:  
• Adverse event  
• Death  
• Failure to meet randomization criteria  
• Lack of efficacy  
• Lost to follow -up 
• Investigator decision  
• Pregnancy  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     43 of 85    20 April 2022  • Protocol deviation 
• Screen failure  
• Site terminated by [CONTACT_1034]  
• Study terminated by [CONTACT_1034]  
• Withdrawal by [CONTACT_752922]. 
Discontinuation of study treatment al so require s discontinuation from the study. If study 
treatment  is permanently  discontinued, the patient  will no t remain in the study. See the SoA  
(Table 1 ) for data to be collected at the time of discontinuation of study treatment  and follow -up 
and for any further evaluations that need to be completed. 
A patient  may withdraw from the study at any time at their own request or may be withdrawn at 
any time at the discretion of the Investigator for safety, behavioral, or compliance reasons. The 
patient  will be permanently discontinued from the study treatment  and the study at that time.  
If the patient  withdraws consent for disclosure of future information, the Sponsor may retain and 
continue to use any data collected before such a withdrawal of consent. 
If a patient  withdraws from the study, he/she may request destruct ion of any samples taken and 
not tested, and the Investigator must document this in the site study records. 
At the time of discontinuing from the study, if possible, an early discontinuation visit should be 
conducted, as shown in the SoA ( Table 1 ). Refer to the SoA for data to be collected at the time of 
study discontinuation and follow -up and for any further evaluations that need to be completed.  
7.1.1 Stoppi[INVESTIGATOR_752879]12852 is a highly selective 5- hydroxytryptamine receptor 4 (5 -HT 4 receptor) agonist. As 
such, the stoppi[INVESTIGATOR_752880] 5-HT 4 receptor agonists. The overall study will be s topped if ≥ 2 patients develop the same 
Grade 3 CTCAE cardiac event or 1 patient develops a CTCAE ≥ Grade 4 cardiac event.  
For cardiac adverse events classified as CTCAE ≥ Grade 3, if  the same cardiac safety concern is 
seen on two separate ECGs, the patien t should be withdrawn from the study and will be referred 
to a cardiologist for the appropriate treatment.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     44 of 85    20 April 2022  7.2 Loss  to Follow-Up /Early Discontinuation from Study Drug  
A patient  will be considered lost to follow -up if they  repeatedly fail to return for scheduled visits 
and are unable to be contact[CONTACT_9298].  
The following actions must be taken if  a patient  fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact [CONTACT_752923] m issed visit as soon as 
possible (and within the visit window, where one is defined) , counsel the patient  on the 
importance of maintaining the assigned visit schedule , and ascertain whether the patient  
wishes to and/or should continue in the s tudy.  
• In cases in which the patient  is deemed lost to follow -up, the I nvestigator or designee must 
make every effort to regain contact [CONTACT_10970]  (where possible, three telephone calls 
and, if necessary , a certified letter to the patient’s  last known mailing address or local 
equivalent methods). These contact [CONTACT_23526]’s medical 
record /eCRF. 
• Should the patient  continue to be unreachable, he/she will be considered to have  withdrawn 
from the study. 
If a patient discontinues study drug pr ior to study termination, the patient will be asked to return 
to the clinic  for an Early Termination vi sit.  This visit will include all the study procedures of the 
Day 35/Visit 8 clinic vis it.  The Day 35 study proce dures and their timing are summarized in the 
SoA ( Table 1).  
8 Study Assessments and Procedures  
Study procedures and their timing are summarized in the SoA  (Table 1 ).  
Immediate safety concerns should be discussed with the Medical Monitor  immediately upon 
occurrence or awareness to determine if the patient  should continue or discontinue study 
treatment . 
Adherence to the study design requirements, including those specified in the SoA  (Table 1 ), is 
essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential patients  
meet all eligibility criteria. The Investigator  should maintain a screeni ng log to record details of 
all patients  screened and to confirm eligibility or record reasons for screening failure, as 
applicable.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030815] information (including direct telephone numbers) to be used in the event of an emergenc y. The Investigator or qualified designee will provide the 
patient  with a patient  identification card immediately after the patient  provides written informed 
consent. At the time of treatment  allocation/randomization, site personnel will add the 
treatment /randomization number to the patient  identification card.  
Medical History  
A medical history will be obtained by [CONTACT_26359]. The medical history will collect all active conditions and any condition diagnosed within the prior 5 years that the Investigator considers to be clinically relevant. Details regarding the disease for which the patient  has enrolled in this study will be recorded separately and not listed as medical history. 
8.1 Efficacy Assessments  
8.1.1 Primary  Efficacy Assessment – Gastric Emptying Breath Test  
The GEBT is a nonradioactive noninvasive test that measures gastric emptying. Patients will 
provide baseline (premeal) breath samples and then consume a standardized 230 kCal meal, 
consisting of a proprietary standardized 13C labeled egg component (which is rehydrated and 
then microwaved for 1.5 minutes) and [ADDRESS_1030816] the stomach empties the meal by 
[CONTACT_145414]- 13 dioxide (13CO2) excretion arising from the digested test meal.  
The GEBT measures the rate of 13CO [ADDRESS_1030817] meal has been emptied from th e stomach. In subjects with delayed 
emptying, 13CO2 excretion rates likewise start to rise after ingestion of the meal, but rates are 
lower and rarely reach a maximum before the end of the evaluation period (240 minutes) as a 
significant portion of the mea l remains in the stomach and digestion and assimilation are 
incomplete . 
Planned timepoints for all efficacy assessments are provided in the SoA  (Table 1 ). 
8.1.2 Secondary Efficacy Assessment – ANMS GCSI -DD 
The ANMS GCSI -DD is designed to assess gastrointestinal symptoms associated with IG and 
DG. The ANMS GCSI -DD symptom assessments are based on a 2 4-hour recall period to 
minimize bias in patient recall.  The instrument asks patients  to rate the severity of five  
symptoms: bloating (feeling like you need to loosen your clothes), nausea, not able to finish a normal -sized meal, feeling excessively full after meals, and upper abdominal pain. The severity 
response is rated by [CONTACT_752924] 24 hours. The severity of symptom response scale ranges from 0 (“none”), 1 (“mild”), 2 (“moderate”), 3 (“severe”) to  4 (“very severe”). In the scoring of vomiting epi[INVESTIGATOR_1841], the number of epi[INVESTIGATOR_752881], with the epi[INVESTIGATOR_752882] 4, so that the scoring is similar to the symptom severity scores of the other items. Therefore, vomiting epi[INVESTIGATOR_124603] s cored as 0=none; 
1=one epi[INVESTIGATOR_1865]; 2=two epi[INVESTIGATOR_1841]; 3= three epi[INVESTIGATOR_49591] 4= four or more epi[INVESTIGATOR_1841]. 
The ANMS GCSI -DD total gastroparesis symptom daily score is generated by [CONTACT_752925] 5, that is the number of items 
within the gastroparesis related symptom score.  Thus, the maximum total symptom score could be (5 symptoms * maximum score 4 divided by 5); hence, the maximum score is 20/5=4. The ANMS GCSI -DD gastroparesis symptom daily score can range from [ADDRESS_1030818] on a patient’s condition. 
In this study, the change from baseline over time for the ANMS -GCSI -DD score  will be assessed 
by [CONTACT_752926]:  
Change from baseline in the ANMS GCSI -DD) (i.e. Day -7 to Day - 1) (predose) and Day 7 (Day 
1 to Day 7)  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     47 of 85    20 April 2022  Change from baseline in the ANMS GCSI -DD ( i.e., Day -7 to Day -1) (predose) and Day  14 (Day 
8 to Day 14)  
Change from baseline in the ANMS GCSI -DD ( i.e., Day -7 to Day -1) (predose) and Day  21 (Day 
15 to Day 21)  
Change from baseline in the ANMS GCSI -DD ( i.e., Day -7 to Day -1) (predose) and Day  28 (Day 
22 to Day 28)  
The ANMS -GCSI -DD sub scores will also be assessed as an Exploratory Endpoint:  
Change from baseline in the sub sc ores (nausea, early satiety, postprandial fullness, upper 
abdominal pain and number of vomiting epi[INVESTIGATOR_1841]) of the ANMS -GCSI -DD over time (Day 7, 14, 
21, 28) by [CONTACT_508203] 7 to Day  14, Day 14 to Day 21 and Day 21 to Day 28. 
The patients will complete  these assessments  using an electronic diary.   
8.1.3 Exploratory Efficacy Assessments  
[IP_ADDRESS]  PAGI -SYM and PAGI -QOL 
The PAGI -SYM will assess the patient’s severity of symptoms related to the GI problem. The 
PAGI -SYM is a 20 -question assessment ( Rentz, 2004) .  The patient will circle the number that 
best describes how severe the symptom has been during the past 2 weeks. PAGI -SYM subscale 
scores are calculated by [CONTACT_752927]; the subscale scores vary 
from 0 (none or absent) to 5 (very severe). The half -scale rule is applied for missing data (i.e., 
the subscale score is calculated using the mean of non -missing items; when more than 50% of 
items are missing, the score is set to missing). The total score is calculated by [CONTACT_752928]. If a subscale score is missing, the PAGI -SYM total score is set to missing.  
If the patient has not experienced the symptom, they would circle 0. If the symptom has been 
very mild, mild, moderate, or severe, they would circle 1, 2, 3 or 4, respectively.  
The PAGI -QOL will assess the patient’s current GI problems such as pain, discomfort or other 
problems and evaluate how these symptoms have affected the patient’s quality of life and 
well-being in the past 2 weeks. There are 30 questions in the assessment, with questions such as 
“Have you had to depend on others to do your daily activities?” and “Have you felt helpless?” with answer options including “none of the time,” “a little of the time,” “some of the time,” “a good bit of the time,” and “all of the time.”  The PAGI -QOL contains 30 items covering five 
subscales:  Daily Activities (10 items), Clothing (2 items), Diet and Food Habits (7 items), 
Relationships (3 items), and Psychological Well -Being (8 items).   Subjects are asked to respond 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     48 of 85    20 April 2022  to each item on a 6 -point Likert scale, ranging from 0 (none of the  time) to 5 (all of the time). 
Subscale scores are calculated by [CONTACT_752929]. The range of scores is 0 –5; higher scor es indicate better  HRQL  (de la 
Loge, 2004)  
In this study, the change from baseline over time for the PAGI -SYM and PAGI -QOL scores  will 
be assessed by [CONTACT_508203] 1 to Day 28. The patients will com plete  these assessments  using 
an electronic diary.  
[IP_ADDRESS]  CGI -S and CGI -I 
The CGI -S provides an overall clinician -determined summary measure that takes into account all 
available information, including a knowledge of the patient’s history, psychosocial 
circumstan ces, symptoms, behavior, and the impact of the symptoms on the patient’s ability to 
function. The CGI actually comprises two companion one -item measures evaluating the 
following: (a) severity of psychopathology from 1 to 7 and (b) change from the initiation of 
treatment on a similar seven -point scale ( Busner, 2007).  
The CGI -S asks the Investigator the question: “Considering your total clinical experience with 
this particular population, how mentally ill is the patient at this time? This is rated o n the 
following 7- point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 
4=moderately ill; 5= markedly ill; 6=severely ill; and 7=among the most extremely ill patients. The rating is based upon observed and reported symptoms, behavi or and function in the past 
7 days. 
The CGI -I will ask the Investigator the question: “Compared to the patient’s condition at 
admission to the study, this patient’s condition is 1=very much improved since the initiation of 
study treatment; 2=much improved;  3=minimally improved; 4=no change from baseline (the 
initiation of study treatment); 5=minimally worse; 6=much worse; and 7=very much worse since the initiation of study treatment.  
In this study, the change from baseline over time for the CGI -S and CGI -I scores will be assessed 
by [CONTACT_508203] 1 to Day 28. The investigator  will complete  these assessments  using an 
electronic diary.  
[IP_ADDRESS]  PGI-S and PGI -C 
Consistent with the recommendations in the FDA Draft Guidance: Gastroparesis: Clinical Evaluation of Drugs for  Treatment, 2019, multiple anchor scales  will also be used to assess the 
impact of treatment on the patient’s disease. The patient global impression of severity (PGI -S) 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     49 of 85    20 April 2022  and patient global impression of change (PGI -C) scales will be used in the proposed Pha se 2A 
study, with the intent of providing accumulated evidence to help interpret a clinically meaningful 
within -patient score change.   
The PGI -S will assess the patient’s severity of symptoms. The choices are: “ none ,” “mild,” 
“moderate,” “severe” and “very  severe.”  
The PGI -C will assess the patient’s impression of how their GI symptoms have changed. The 
patient will choose 1 of 7 answers, including: “very much improved,” “much improved,” 
“minimally improved,” “no change,” “minimally worse,” “much worse”  and “very much worse.”  
In this study, the change from baseline over time for the PGI -S and PGI -C scores will be 
assessed by [CONTACT_508203] 1 to Day 28. The patients will complete  these assessments using an 
electronic diary.  
8.2 Safety Assessments  
Planned timep oints for all safety assessments are provided in the SoA ( Table 1 ). 
• AEs (by [CONTACT_24975], severity, and relatedness) at each visit.  
• Changes in safety clinical l aboratory testing and vital signs at each site visit.  
• Changes in ECGs at each site visit  and the potential correlation of the PK with changes in the 
ECG . 
• Change from baseline in the C -SSRS scores over time by [CONTACT_508203] 1 to Day 28. 
 
8.2.1 Physical Examinations  
Complete physical examinations (excluding pelvic exam in women and genital exam in men, and 
rectal exam in both genders) are to be performed  at Screening  (Visit 1) and Day 28 (Visit 6) . 
Symptom -directed (abbreviated) physical examinations  may be conducted as required at  Visit 3 
(Day 1) Visit 4 (Day 7), Visit 5 (Day 14), and Visit 8 (Day 35).  
Patients  should be weighed with no shoes, in light clothing, without any outerwear. Height 
should be measured only at the first study visit . Any abnormalit y noted on the physical 
examination done at or following Visit [ADDRESS_1030819] igators should pay special attention to clinical signs related to previous serious illnesses. 
8.2.2 Vital Signs  
• Heart rate (HR), respi[INVESTIGATOR_697], systolic and diastolic blood pressure (BP), weight and 
temperature will be assessed; the method for measuring tempe rature will be per the site’s 
preference.  
• BP and HR measurements will be assessed in the sitting position with a completely automated device. Manual techniques will be used only if an automated device is not available.  
• BP and HR measurements should be prec eded by [CONTACT_2669] [ADDRESS_1030820] for the patient in a 
quiet setting without distractions (eg, television, cell phones).  
• Vital signs are to be taken before blood collection for laboratory tests. 
8.2.3 Electrocardiograms  
A 12 -lead ECG will be obtained as outline d in the SoA  (Table 1 ) using an ECG machine after  
the patient  has rested for 5 minutes in supi[INVESTIGATOR_2547]. At Visit 3 (Randomization) and Visit 6  
(Day 28) , the ECG will be performed prior to the 4-hour PK draw. At Visit 4 and Visit 5, the 
ECG will be performed approximately 4 hours after the patient’s dose. The Inve stigator will 
report whether the  ECG is normal or abnormal and if the result is considered clinically 
significant or not. 
All clinically significant ECG abnormalities occurring during the study should be documented as  
AEs. The ECG performed at Screening  will be recorded as the baseline assessment. Standard 
ECG parameters, including heart rate, QRS, PR, QT, Bazett’s correction for QT (QTcB), and 
Fridericia’s correction for QT (QTcF) intervals will be measured. The ECGs will be overread by  
[CONTACT_752930].  
8.2.[ADDRESS_1030821] of clinical laboratory tests to be performed and the SoA  (Table 1 ) 
for the timing and frequency. 
The Investigator must review the laboratory report, document this review, and record any 
clinically significant  changes occurring during the study as an AE . The laboratory reports must 
be filed with the source documents . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     51 of 85    20 April 2022  Abnormal laboratory findings associated with the underlying disease  are not considered 
clinically significant unless judged by [CONTACT_941] I nvestigator to be more severe than expected for the 
patient’s  condition. 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within [ADDRESS_1030822] dose of study treatment  should be repe ated until the 
values return to normal or baseline  or are no longer considered clinically significant by [CONTACT_752931] . 
• If such  values do not return to normal/baseline within a period of time judged reasonable by 
[CONTACT_737] , the etiology should be identified, where possible, and the S ponsor notified. 
• All protocol -required laboratory tests , as defined in Appendix 2, must be conducted in 
accordance with the laboratory manual and the SoA  (Table 1 ). 
• If laboratory values from laboratory tests  not specified in the protocol and performed at the 
institution’s local laboratory result in the need for a change in patient  management or are 
considered clinically relevant by [CONTACT_941] I nvestigator ( e.g., are considered to be  an SAE or an AE 
or require dose modification), then the resul ts must be recorded  in the eCRF . 
8.2.[ADDRESS_1030823] will be 
performed at Screening ( Visit 1 ) and a u rine pregnancy test at subseq uent visits . Refer to the 
SoA ( Table 1 ) for testing timepoints.  
Details of all pregnancies in females and female partners of male patients  will be collec ted after 
the start of study treatment  and until the end of the study period (Visit 7) . If a pregnancy is 
reported, the Investigator should inform the Sponsor within 24 hours of  learning of the 
pregnancy and should follow the procedures outlined in Appendix 4. Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered to be SAEs. 
8.2.[ADDRESS_1030824]  an increased risk of suicidal ideation or behavior.  
Patients  being treated with PCS12852 should be monitored appropriately and observed closely 
for suicidal ideation and behavior  (SIB)  or any other unusual changes in behavior, especially at 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     52 of 85    20 April 2022  the beginning and end of the course of study treatment . Patients  who experience signs of suicidal 
ideation or beha vior should undergo a risk assessment. All factors contributing to SIB should be 
evaluated and consideration should be given to discontinuation of the study treatment . 
Baseline assessment of SIB  will be monitored during the study using the C -SSRS by [CONTACT_752892] 1 to Day 7 , Day 14 and Day 28 scores. R efer to the SoA ( Table 1 ) for timepoints.  
8.3 Adverse Events , Serious Adverse Events , and Other Safety Reporting  
The definitions of A Es and SAE s can be found in Appendix 3. 
Adverse events will be reported by [CONTACT_752932].  
The Investigator and any qualified designees are responsible for detecting, documenting, and 
reporting events that me et the definition of an AE or SAE and remain responsible for following 
up A Es that are serious, considered related to the study treatment  or the study, or that caused the 
patient  to discontinue the  study treatment  (see Section  7). 
The method of recording, evaluating, and assessing causality of A Es and SAEs and the 
procedures for completing and transmitting SAE reports are  provided in Appendix 3. 
8.3.1 Time Period and Frequency for C ollecting AE and SAE I nformation  
All A Es will be collected from the signing of the ICF .  All SAEs will be collected and followed  
until 30 days after the final Visi t (Visit 8) , at the timepoints specified in the SoA  (Table 1 ). 
All SAE s will be recorded and reported to the S ponsor  or designee within 24 hours  of awareness , 
as indicated in  Appendix 3. The Investigator will submit any updated SAE data to the S ponsor  
within 24 hours of it being available.  
Investigators are no t obliged to actively seek information on A Es or SAE s after the conclu sion of  
study participa tion. However, if the Investigator learns of any SAE, including a death, at any 
time after a patient  has been discharged from the study, and he/she considers the event to be 
reasonably related to the study treatment  or study participation, the Investigator must promptly 
notify the S ponsor . 
8.3.2 Method of Detecting A Es and SAE s 
Care will be taken not to introduce bias when detecting A Es and/or SAE s. Open- ended and 
non-leading verbal questioning of the patient  is the preferred method to inquire about 
AE occurrence.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     53 of 85    20 April 2022  8.3.3 Follow -up of A Es and SAE s 
After the initial AE/SAE report, the Investigator is required to proactively follow each patient  at 
subsequent visits/contacts. All A Es and SA Es, (as defined in Appendix 3) , will be followed until 
resolution, stabiliz ation , until the event is otherwise explained, or the patient  is lost to follow -up 
(as defined in Section  7.2). Further information on follow -up procedures is given in Appendix 3. 
8.3.4 Regulatory Reporting Requirements for SAE  
Prompt notification within 24 hours  (see Appendix 3) by [CONTACT_95876] S ponsor  of an 
SAE is essential so that legal obligations and ethical responsibilities towards the safety of 
patients  and the safety of a study treatment  under clinical investigation are met.  
The S ponsor  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The 
Sponsor  will comply with country- specific regulatory requirements relating to saf ety reporting to 
the regulatory authority, Institutional Review Board ( IRB)/Independent Ethics Committee ( IEC), 
and Investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary.  
An Investigator who receives an Investigator S afety R eport describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the S ponsor will review and then file 
it along with the I nvestigator’s B rochure  and will notify the IRB/IEC, if appropriate according to 
local requirements.  
8.3.[ADDRESS_1030825] pregnancy information on the appropriate 
form and submit it to  the Sponsor  within 24 hours of learning of the  pregnancy and should 
follow the procedures outlined in Appendix 4. 
Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered to be SAE s and will be reported as such . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     54 of 85    20 April 2022  8.4 Pharmacokinetic s 
Blood samples will be collected for measurement of PCS12852 in plasma via a specific and 
sensitive validation bioanalytical method, at timepoints as specified in the SoA ( Table 1 ). 
Clinical staff are encouraged to take the blood samples for PK analysis at the scheduled time 
point; however, deviations from the scheduled sample times are not considered protocol deviations. The actual date and time (24 -hour clock time) of sample  collections will be recorded 
in the source document and transcribed into the eCRF. Instructions  for the collection and 
handling of biological samples will be provided in the Study Manual .  
Samples will be used to evaluate the PK of  PCS12852. Samples collected for analyses of 
PCS12852 plasma  concentration may also be used to evaluate safety or efficacy aspects that 
address concerns  arising during or after the study. 
Genetic analyses will not be performed on these blood samples. Subject confidentiality will be  
maintained.  
Any changes in the timing or addition of time points for any planned study assessments must be  
documented and approved by [CONTACT_752933] a protocol amendment. The IRB/IEC will be informed 
of any safety issues that require alteration of the safety monitoring scheme or amendment of the  
ICF. 
  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     55 of 85    20 April 2022  9 Statistical Considerations  
The statistical analysis pla n (SAP)  will be developed and finalized before database lock  and will  
include a more technical and detailed description of the statistical analyses described in this 
section. This section is a summary of the planned statistical analyses of the most importa nt 
endpoints including primary and key secondary endpoints. 
9.[ADDRESS_1030826] 1 plasma sample with a 
quantifiable concentration of PCS12852.  
Full Analysis Set Patients who are randomized . 
9.2 Statistical Analy ses 
9.2.1 General Considerations  
Approximately 24 patients (approximately 8 patients in each of the three treatment groups ) with 
moderate to severe gastroparesis  who have documented delayed gastric emptying are planned to 
be randomized (1:1:1) in the study. The randomization to treatment groups will be stratified by 
[CONTACT_752934]  (idiopathic, diabetic), enrolling at least 2  patients of each type of 
gastroparesis  (idiopathic, diabetic) in each treatment group. 
9.2.2 Primary Efficacy  Analysis 
The change in the gastric emptying rate AUC  as measured by [CONTACT_145425],  from baseline to Day 28 
will be analyzed in the FAS using an analysis of covariance (ANCOV A) model with treatment 
group (three levels) as a factor and the baseline GEBT as a covariate. Each of the two primary 
comparisons  (0.1 mg vers us placebo, 0.5 mg versus placebo), will be conducted using a two-
sided Dunnett’s test at the overall alpha=0.05 significance level.  
Other e fficacy analyses:  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     56 of 85    20 April 2022  All secondary endpoints will be conducted using the same approach as described for the primary 
analysis. Each treated group will be compared to placebo using Dunnett’s test . All secondary 
analyses will be based on the use of two- sided tests at the alpha=0.05 overall level of 
significance, with no adjustment for multiplicity.  
Subgroup analysis:  
 
A subgroup analysis of idiopathic gastroparesis patients compared to diabetic gastroparesis 
patients will be done for all efficacy analysis endpoints.  
Pharmacokinetic analysis:  
Plasma concentrations will be used to estimate the pharmacokinetic parameters fo r PCS12852 on 
Day 1 and Day 28 using noncompartmental methods in WinNonlin®. The following parameters 
will be calculated as data permits: 
• Cmax: maximum observed plasma concentration  
• Tmax: time at which the maximum plasma concentration was observed  
• t½: (the apparent first -order terminal elimination half -life) 
• AUC 0-last: the area under the plasma concentration versus time curve, from time [ADDRESS_1030827] measurable concentration  
• AUC ∞: the area under the plasma concentration vs. time curve from time 0  to infinity  
• λz:  apparent first order terminal elimination rate constant 
 
A dose proportionality analysis will be conducted for log- transformed C max, AUC 0-last, and 
AUC ∞ using the power model. . In addition, the relationship between gastric emptying rate and 
drug exposure will be assessed, as data permit.  Exposure -response for safety measures may also 
be explored.   
In addition, a population PK model may be used to describe the PK of PCS12852, if  appropriate 
based on the data collected.    A previously developed population PK model describing the PK of 
PCS12852 in patients with functional constipation, using a two- compartment model with first 
order absorption, may be used to predict the PK in patie nts in this study.  
Further details of all analyses will be described in the SAP.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030828] moderate symptom severity. The ANMS GCSI -DD sc ale will be used to assess the change 
from baseline in symptoms. 
The ANMS GCSI -DD symptom assessments are based on a 24 -hour recall period to minimize 
bias in patient recall. The ANMS GCSI -DD total gastroparesis symptom daily score is generated 
by [CONTACT_752935] (nausea, early satiety, postprandial 
fullness, upper abdominal pain, and number of vomiting epi[INVESTIGATOR_1841]) and then dividing by 5, that is the number of items within the gastroparesis related symptom score. Thus, the  maximum total 
symptom score could be (5 symptoms x maximum score 4 divided by 5); hence, the maximum 
score is 20/5=4. The ANMS GCSI -DD gastroparesis symptom daily score can range from [ADDRESS_1030829] greater symptom severity.  
9.2.4 Other Patient -reported outcomes (PRO) Assessments – Exploratory 
Endpoints  
The PAGI -SYM is a patient -reported outcome that asks patients the severity of their symptoms 
over the last 2 weeks. The PAGI -SYM was developed to measure symptom severity for 
gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The PAGI -SYM is 
composed of 20 items and 6 subscales: heartburn/regurgitation (7 items), nausea/vomiting (3 
items), postprandial fullness/early satiety (4 items), bloating (2 items), upp er abdominal pain (2 
items), and lower abdominal pain (2 items). Subscale scores are calculated by [CONTACT_112239]; scores vary from 0 (none or absent) to 5 (very severe). The half -
scale rule is applied for missing data (i.e. , the subscale score is calculated by [CONTACT_752936]-missing items; when more than 50% of items are missing, the score is set to missing) . The 
change from baseline in the PAGI -SYM will be analyzed using the same statistical approach as 
described for  other analys es. 
The PGI -C is a patient -reported questionnaire with a 7- point rating scale where the participant 
rates his/her own improvement in overall symptoms relative to the baseline assessment. It is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.  
The PGI -S is a patient reported questionnaire with a single question to measure disease severity 
on a 5- point rating scale. It is rated as “none,” “mild,” “moderate,” “severe,” and “very severe.”  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     58 of 85    20 April 2022  The PAGI -QOL is a 30 -item instrument assessing quality of life in patients with gastroparesis. 
The questionnaire covers 5 domains: Daily Activities, Clothing, Diet and Food Habits, 
Relationship, and Psychological Well -Being and Distress. The effect on overall quality of life 
and well -being over the past 2 weeks is rated on a scale of 0 (none of the time) to 5 (all of the 
time) for each item.  
Clinicians complete the CGI -S, which is a 7- point scale on which the clinician rates the severity 
of the patient’s gastroparesis at the time of assessment and refers to the degr ee of illness at the 
time of the visit and during the 2 weeks before the visit. The CGI -S is rated on the following 7-
point scale: 1: normal, not at all ill; 2: borderline ill; 3: mildly ill; 4: moderately ill; 5: markedly 
ill; 6: severely ill; 7: among th e most extremely ill patients.  
The CGI -I is a 7 -point scale in which the clinician rates the change from the initiation of 
treatment. The CGI -I is rated as: 1: very much improved since the initiation of study treatment; 
2: much improved; 3: minimally impro ved; 4: no change from baseline (the initiation of study 
treatment); 5: minimally worse; 6: much worse; and 7: very much worse since the initiation of 
study treatment.  
9.2.5 Safety  Analyses  
The safety analyses will be performed using the Safety Population and include AEs, changes in 
physical exam findings, vital signs, ECGs and clinical laboratory values.  
Adverse events will be coded using the current version of the Medical Dictionary for Regulatory 
Activities (MedDRA version 23.0 or higher). The number and percent of patients reporting at least one AE will be summarized by [CONTACT_752937], relationship to study treatment , amount of drug exposure , and time. Each patient will 
contribute only once (i.e., first occurrence) to each of the incidence rates, regardless of the number of occurrences. Severity of A Es will be assessed based on the National Cancer Institute 
(NCI) CTCAE  Version 5.0. For report ing of AE severity in patients with more than one 
occurrence of the same AE, the patient will only be reported once based on the highest severity 
of the AE observed. Patients who have a n SAE or who discontinue the study due to an AE 
deemed to be related to  study treatment  will be described in patient narratives. 
Vital signs, clinical laboratory, and ECG results will also be presented and summarized by [CONTACT_752938]. All 
safety  data collected in the clinical database, including physical exam findings and abnormal 
ECG results, will be presented in data listings.  The safety categories will be summarized as 
appropriate (eg, categorial or continuous descriptives, shift tables) and w ill be fully defined in 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     59 of 85    20 April 2022  the SAP.  The potential relationship between abnormal ECG results and PK will also be evaluated 
and fully defined in the SAP.  
9.3 Sample Size Determination  
Based on the results of a prior study (Study 102), estimates of the standard deviation (SD) of the 
AUC change from baseline range from [ADDRESS_1030830] at the alpha=0.025 level of significance, a sample size of 8 patients per arm (2 4 
total patients) will provide 80% power to detect a bet ween -group mean difference of 25.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     60 of 85    20 April 2022  10 Supporting Documentation and Operational Considerations  
10.1 Appendix  1: Regulatory , Ethical, and Study Oversight Considerations  
10.1.1  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences  international 
ethical guidelines . 
• Applicable ICH Good Clinical Pract ice (GCP) guidelines . 
• Applicable laws and regulations . 
The protocol, protocol amendments, ICF, Investigator ’s Brochure, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by [CONTACT_752939]/IEC  before the study is initiated.  
Any amendments to the protocol will require IEC/IRB approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediat e 
hazard to study patients . 
Protocols and a ny substantial amendments to the protocol will require health authority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study patients . 
The Investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by [CONTACT_5040]/EC.  
• Notifying the IRB/IEC of SAE or other significant safety findings as required by [CONTACT_1744]/IE C 
procedures . 
• Providing oversight of the overall conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH  GCP  guidelines, the IRB/IEC, and all other applicable local 
regulations . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     61 of 85    20 April 2022  10.1.2  Informed Consent Process  
The Investigator or his/her  representative will explain the nature of the study , including the risks 
and benefits, to the patient  and answer all  questions reg arding the study.  
Patients  must be informed that their participation is voluntary. P atients will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local reg ulations, ICH 
guidelines, privacy and data protection requirements, where applicable, and the IRB/IEC or 
study center.  
The medical record must include a statement that written informed consent was obtained before 
the patient  was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Patients  must be re -consented to the most current version of the ICF(s) during their participation 
in the study. 
A copy of the ICF(s) must be provided to the patient.  
If a protocol amendment is required, the ICF may need to be revised to reflect the changes to the 
protocol. If the ICF is revised, it must be reviewed and approved by [CONTACT_69869]/ IRB and  
signed by [CONTACT_752940]. 
10.1.3  Data Protection  
Patients  will be assigned a unique identifier by [CONTACT_941] S ponsor  via the IRT system . Any patient  
records or datasets that are transferred to the S ponsor will contain the identifier only; patient  
names or any information which would make the patient  identi fiable will not be transferred.  
The patient  must be informed that their  personal study- related data will be used by [CONTACT_941] S ponsor 
in accordance with local data protection law. The level of disclosure must also be explained to 
the patient  who will be required to give consent for their data to be used as described in the 
informed consent . 
The patient  must be informed that their  medical records may be examined by [CONTACT_752941] S ponsor, by [CONTACT_99473]/IEC members, and by [CONTACT_6668].  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     62 of 85    20 April 2022  10.1.4  Dissemination of Clinical Study Data  
A summary of the results of the clinical study together with a summary that is understandable to 
a layperson will be provided after the global end (or early termination) of the study in all 
countries concerned to ensure full availability of all clinical data under this protocol, within 12 months . 
10.1.5  Data Quality Assurance  
All patient  data relating to the study will be recorded on e lectronic CRFs  unless transmitted to 
the S ponsor or designee electronically ( e.g., laboratory data). The Investigator is responsible for 
verifying that data entries are accurate and correct by [CONTACT_104265] t he CRF.  
The Investigator must maintain  accurate documentation (source data) that supports the 
information entered in the eCRF . 
The Investigator must permit study -related monitoring, audits, IRB/IEC review, and R egulatory 
Agency inspections and provide direct a ccess to source data documents.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
The S ponsor assumes accountability for actions delegated  to other individuals ( e.g., contract 
research organizations ). 
Study monitors will pe rform ongoing source data verification to confirm that data entered into 
the eCRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of patients are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements. 
Records and documents, including signed ICF s, pertaining to the conduct of this study must be 
retained by  [CONTACT_13177] [ADDRESS_1030831] be available.  
The specific procedures to be used for data entry and query resolution using the eCRF will be provided to study sit es in a training manual. In addition, site personnel will receive training on 
the eCRF.  
10.1.6  Source Documents  
Source documents provide evidence for the existence of the patient  and substantiate the integrity  
of the data collected. Source documents are filed at the I nvestigator’s site.  
Data reported in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The Investigator may ne ed to 
request previous medical records or transfer records, depending on the study. Also, current medical records must be available.  
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the e CRF.  
Study monitors will perform ongoing source data verification to confirm that data entered into the e CRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of patients  are being protected; and t hat the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
10.1.[ADDRESS_1030832] site open and will be  the study start date . 
Study/Site Termination  
The S ponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the S ponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study site closure visit has been performed.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     64 of 85    20 April 2022  The Investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_941] S ponsor or I nvestigator may include but are 
not limited to:  
• Failure of the I nvestigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the S ponsor ’s procedures, or GCP guidelines . 
• Inadequate recruitment of patients  by [CONTACT_941] I nvestigator . 
• Total number of patients  included earlier than expected.  
• Discontinuation of further study treatment  development. 
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigat or shall promptly inform the patient and 
should assure appropriate patient therapy and/or follow -up. 
10.1.8  Protocol Approval and Amendment  
Before the start of the study, the study protocol and/or other relevant documents will be approved 
by [CONTACT_6179]/IRB/Competent Authorities, in accordance with local legal  requirements. The 
Sponsor must ensure that all ethical and legal  requirements have been met before the first patient 
is enrolled in the study. 
This protocol is to be followed exactly. To alter the protocol, amendments must be written, 
receive approval from the appropriate personnel, and receive IRB/IEC/Competent Authority 
approval prior to im plementation (if appropriate). In the US : Following approval, the protocol 
amendment(s) will be submitted to the Investigational New Drug Application under which the study is being conducted.  
Administrative changes (not affecting the patient benefit/risk r atio) may be made without the 
need for a formal amendment. All amendments will be distributed to all protocol recipi[INVESTIGATOR_840], with appropriate instructions. 
[IP_ADDRESS]  Access to Source Data  
During the study, a monitor will make site visits to review protocol compliance, compare eCRF 
entries and individual patient’s  medical records, assess drug accountability, and ensure that the 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     65 of 85    20 April 2022  study is being conducted according to pertinent regulatory requirements.  The eCRF entries will 
be verified with source documentation. The review of medical records will be performed in a 
manner to ensure that patient confidentiality is maintained.  
Checking of the  eCRF entries for completeness and clarity, and cross -checking with source 
documents, will be required to monitor the progress of the study. Moreover, regulatory 
authorities of certain countries, IRBs, IECs, and/or the Sponsor’s Clinical Q A Group may wish 
to carry out such source data checks and/or on- site audit inspections. Direct access to source data 
will be required for these inspections and audits; they will be carried out giving due 
consideration to data protection and medical confidentiality. The Inve stigator assures the 
Sponsor  of the necessary support at all times. 
  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     66 of 85    20 April 2022  10.2 Appendix  2: Clinical Laboratory Tests  
• All clinical laboratory tests should be done after patients have fasted for at least 8 hours.  
• The tests will be performed by [CONTACT_2237] , unless prior approval is received 
from the Sponsor . 
• Protocol -specific requirements for inclusion or exclusion of patients are details in 
Sections 5.1 and 5.2. 
• Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_941] I nvestigator or required by [CONTACT_427] . 
• Investigators must document their review of each laboratory safety report.  
Table 6  Protocol -required Safety Laboratory Tests  
Laboratory Tests Parameters  
Hematology  Platelet c ount 
RBC c ount 
Hemoglobin  
Hematocrit  
RBC i ndices:  
Mean corpuscular volume ( MCV ) 
Mean corpuscular hemoglobin ( MCH ) 
% Reticulocytes  WBC count with differential: 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Clinical chemistry  BUN  
Potassium  
Creatinine  
Sodium  
Glucose , fasting  
Calcium  
Phosphorus  
Bicarbonate  AST/SGOT  
Total and direct bilirubin  
ALT/SGPT 
Total protein  
Alkaline phosphatase  
Chloride  
Albumin  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     67 of 85    20 April 2022  Routine u rinalysis  Specific gravity  
pH, glucose, protein, blood, ketones, by [CONTACT_13183] (if blood or protein is abnormal)  
Pregnancy t esting  Highly sensitive serum and/or urine  hCG  pregnancy test (as needed for women 
of childbearing potential)  at timepoints  detailed in Section  8.3.5.  
Other screening 
tests  HbA1c and TSH will be done at Screening only  
Follicle -stimulating hormone and estradiol (as needed in women of 
non-childbearing potential only)  
Urine alcohol and drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opi[INVESTIGATOR_858], THC  and benzodiazepi[INVESTIGATOR_1651])  
Serolo gy (HIV antibody, hepatitis B surface antigen ( HbsAg ), and HCV 
antibody)  [HCV PCR will be done for any HCV Ab positive result]  
All study  required laboratory assessments will be performed by a central 
laboratory.  
 
NOTES:  
1. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_31857]/IEC. 
ALT= alanine aminotransferase; AST= aspartate aminotransferase; BUN=blood urea nitrogen; hCG= human 
chorionic gonadotropin; HCV = hepatitis C; HIV = h uman immunodeficiency virus ; IEC= independent ethics 
committee; INR= international normalized ration; IRB= institutional review board; RBC= r ed blood cell; 
SGOT= s erum glutamic -oxaloacetic transaminase; SGPT= serum glutamic -pyruvic transaminase; THC = 
tetrahydr ocannabinol ; TSH = t hyroid stimulating hormone ; WBC= w hite blood cell . 
  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     68 of 85    20 April 2022  10.3 Appendix  3: AEs and SAEs : Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
10.3.[ADDRESS_1030833] medical occurrence in a patient or clinical study patient , temporally 
associated with the use of a study treatment , whether or not considered related to the study 
treatment . 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study treatment. 
 
Events Meeting  the AE Definition  
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments ( e.g., ECG, radiological scans, vital signs measurements), including those 
that worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator ( e.g., not related to progression of underlying disease).  
Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition. 
New condition detected or diagnosed after study treatment  admin istration even though it may 
have been present before the start of the study.  
Signs, symptoms, or the clinical sequelae of a suspected treatment- treatment interaction.  
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment  or 
a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent . Such overdoses should 
be reported reg ardless of sequelae.  
Lack of efficacy or failure of expected pharmacological action per se will not be reported as an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     69 of 85    20 April 2022  symptom s, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or 
SAE if they fulfill  the definition of an AE or SAE. 
 
Events NOT Meeting the AE Definition  
Any clinically significant abnormal laboratory findings or other abnormal safe ty assessments 
that are associated with the underlying disease, unless judged by [CONTACT_321357]’s  condition. 
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/dis order being studied, unless more severe than expected for the patient’s  condition. 
Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that leads to the 
procedure is the AE.  
Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]). 
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
 
10.3.2  Definition of SAE  
An SAE is an  AE that: 
a. Results in death  
b. Is life -threatening  
The term life -threatening  in the definition of serious refers to an event in which the patient  
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     70 of 85    20 April 2022  c. Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_752883]  (usually involving at 
least an overnight stay) at the hospi[INVESTIGATOR_752884]/or treatment  that 
would not have been appropriate in the physician’s office or outpatient setting. Complications 
that occur during hospi[INVESTIGATOR_42244]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether hospi[INVESTIGATOR_51956], the AE should be considered serious.  
Hospi[INVESTIGATOR_21358] a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct normal life functions. 
This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) that may interfere with or prevent everyday life functions but do not 
constitute a substantial disrupt ion. 
e. Is a congenital anomaly/birth defect  
f. Other situations  
Medical or scientific judgment should be exercised by [CONTACT_752942]. These events should usually be considered serious.  
Examples of such events are intensive treatment in an emergency room or at home  for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse . 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     71 of 85    20 April 2022  10.3.3  Recording and Follow-up of AE and SAE  
AE and SAE Recording  
When an AE/SAE occurs, it is the responsibility of the  Investigator to review all 
documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to the 
event.  
The Investigator will then record all relevant AE/SAE information.  
It is not  acceptable for the Invest igator to send photocopi[INVESTIGATOR_113502]’s  medical records to 
the Sponsor  in lieu of completion of the AE/SAE eCRF  page . 
There may be instances when copi[INVESTIGATOR_47956]. In this case, all patient  identi fiers, with the exception of the patient  number, will be 
blinded on the copi[INVESTIGATOR_47957]. 
The I nvestigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE. 
 
Assessment of Intensity  
The clinical severity of an AE will be graded using the NCI CTCAE Version 5.0.  
 
The severity of all adverse events should be graded according to the Common Terminology 
Criteria for Adverse Events (CTCAE)  v.5.0.  These criteria can be found at http://ctep.cancer.gov/reporting/ctc.html .  For those adverse event terms not listed in the 
CTCAE, the following grading system should be used:  
• CTCAE Grade 1: Mild; asymptomatic or mild symptoms; clinical or 
diagnostic observations only; intervention not i ndicated.    
• CTCAE Grade 2:  Moderate; minimal local or noninvasive intervention indicated; limiting age -appropriate instrumental activities of daily 
living.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     72 of 85    20 April 2022  • CTCAE Grade 3: Severe or medically significant but not immediately 
life-threatening; hospi[INVESTIGATOR_48622]; disabling; limiting self -care activities of daily living  
• CTCAE Grade 4:  Life threatening consequences; urgent intervention 
indicated.  
• CTCAE Grade 5:  Death related to the adverse event.   
The investigator i s to evaluate whether the AE meets serious criteria. An event is defined as 
‘serious’ when it meets at least one  of the predefined outcomes as described in the definition 
of an SAE, NOT when it is rated as severe.  
Assessment of Causality  
The I nvestigator is obligated to assess the relationship between study treatment  and each 
occurrence of each AE/SAE.  The Investigator will use clinical judgment to determine the 
relationship. 
A reasonable possibility  of a relationship conveys that there are fac ts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the eve nt to study treatment  administration will be 
considered and investigated. 
The I nvestigator will also consult the I nvestigator’s Brochure  and/or Product Information, for 
marketed products, in their  assessment.  
For each AE/SAE, the I nvestigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
There may be situations in whi ch an SAE has occurred, and the I nvestigator has minimal 
information to include in the initial report in the elect ronic data collection tool . However, it is 
very important that the I nvestigator always make an assessment of causality for every 
event before the initial transmission of the SAE data to the electronic data collection tool . 
The I nvestigator may change their  opi[INVESTIGATOR_9242] -up information and 
send an SAE follow -up report with the updated causality assessment. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     73 of 85    20 April 2022  The following “binary” decision choice will be used by [CONTACT_752943]:  
• Related: R easonable possibility of a relatedness  
• Not related: No reasonable possibility of relatedness. 
The following factors should also be considered:  
• The temporal sequence from study drug administration-  
The event should occur after the study drug is given. The length of time from study drug 
exposure to event should be evaluated in the clinical context of the event.  
• Underlying, concomitant, intercurrent diseases - 
Each report should be evaluated in the context of the natural history and course of the 
disease b eing treated and any other disease the subject may have.  
• Concomitant drug-  
The other drugs the subject is taking or the treatment the subject receives should be examined to determine whether any of them might be recognized to cause the event in question. 
• Known response pattern for this class of study drug-  
Clinical and/or preclinical data may indicate whether a particular response is likely to be a class effect.  
• Exposure to physical and/or mental stresses - 
The exposure to stress might induce adverse changes  in the recipi[INVESTIGATOR_23567] a 
logical and better explanation for the event. 
• The pharmacology and pharmacokinetics of the study drug-  
The known pharmacologic properties (absorption, distribution, metabolism, and excretion) of the study drug should be cons idered.  
 
The causality assessment is one of the criteria used when determining regulatory  reporting 
requirements.
 
 
Follow -up of AE and SAE  
The I nvestigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_48018]/or causality of the AE or SAE as fully as possible. This may include 
additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030834] be reported to Medpace Clinical Safety or the Sponsor/designee.  
 
To report the SAE, complete the SAE form electronically in the electronic data capture (EDC) 
system for the study. When the form is complet ed, Medpace Safety personnel will be notified 
electronically by [CONTACT_248129]. If the event meets serious criteria and it is not possible to access the EDC system, send an email to Medpace Safety at medpace -
safetynotification@me dpace.com or call the Medpace SAE hotline (phone number listed 
below), and fax/email the completed paper SAE form to Medpace (contact [CONTACT_20986]) within [ADDRESS_1030835] be  entered within 24 hours of the system becoming available.  
Medpace SAE hotline – [LOCATION_003]:  
Telephone: +1 -[PHONE_2256], dial “3” or +1 -[PHONE_2257], dial “3”  
Facsimile: +1 -[PHONE_4714] or +1- [PHONE_5562] 
E-mail: medpace -[EMAIL_1925]  
Follow -Up Reports  
The investigator must continue to follow the subject until the SAE has subsided or until the condition becomes chronic in nature, stabilize s (in the case of persistent impairment) or the 
subject dies.  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030836] update the SAE 
form electronically in the EDC system for the study and submit any supporting documentation 
(e.g., subj ect discharge summary or autopsy reports) to Medpace Clinical Safety via fax or e -
mail. If it is not possible to access the EDC system, refer to the procedures outlined above for initial reporting of SAEs.  
 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     76 of 85    20 April 2022  10.4 Appendix  4: Contraceptive Guidance and Collection of Pregnancy 
Information  
Definitions 
Woman of Childbearing Potential  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered WOCBP:  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
Note: Documentation can come from the site personnel’s: review of the patient’s  medical 
records, medical examination, or medical history interview.  
3. Premenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an alternative med ical cause. A n FSH level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therapy (HRT). However, in the absence 
of 12 months of amenorrhea, a single FSH measurement  is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to use 
one of the non- hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must disconti nue HRT to 
allow confirmation of postmenopausal status before study enrollment.
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     77 of 85    20 April 2022  Contraception  Guidance  
Female Patients 
Female patients of childbearing potential are eligible to participate if they agree to use a highly 
effective or accepted effective metho d of contraception consistently and correctly as described 
below. 
Highly Effective Contraception Methods  
Highly Effective Contraceptive Methods That Are User Dependenta 
Failure rate of < 1% per year when used consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulation  
• Oral 
• Intravaginal  
• Transdermal  
Highly Effective Contraceptive Methods That Are User Independenta 
Implantable progestogen -only hormonal contraception associated with inhibition of ovulation  
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
Bilateral tubal occlusion  
Vasectomized Partner  
A vasectomized partner is a highly effective contraception method provided that the partner is  
the sole male  sexual partner of the woman of childbearing potential ( WOCBP ) and the 
absence of sperm has been confirmed. If not, an additional highly effective  method of 
contraception should be used. 
Sexual Abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual  intercourse during the entire period of risk associated with the study treatment. 
The reliability of sexual abstinence needs to be evaluated in relation to t he duration of the 
study and the preferred and usual lifestyle of  the patient . 
a Typi[INVESTIGATOR_35818]. Use should be consistent  
with local regulations regarding the use of contraceptive methods for patients participating in clinical studies.  
Accepted Effective Contraceptive Methods  
Acceptable birth control methods that result in a failure of more than 1% per year include:  
• Progestogen- only oral hormonal contraception, where inhibition of ovulat ion is not the 
primary mode of action 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     78 of 85    20 April 2022  • Male or female condom with or without spermicide  
• Cap, diaphragm, or sponge with spermicide  
• Nonhormonal intrauterine device  
A combination of male condom with either cap, diaphragm, or sponge with spermicide (double 
barrier methods) are also considered acceptable, but not highly effective, birth control methods. 
Pregnancy Testing  
At a minimum, a pregnancy test should be performed as per the SoA  (Table 1 ). 
• Women of childbearing potential ( WOCBP ) should only be included in the study after a 
confirmed menstrual period and a  negative highly sensitive serum pregnancy test  
Pregnancy testing will be  performed whenever a menstrual cycle is missed or when pregnancy is  
otherwise suspected.  
Collection of Pregnancy Information  
Female Patients Who Become Pregnant  
• The Investigator will collect pregnancy information on any female patient who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the Sponsor within 24 hours of learning of a patient’s pregnancy.  
• The patient will be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow -up information on the patient and the neonate, and the information 
will be forwarded to the Sponsor. Generally, follow -up will not be required for longer 
than 6 to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for 
the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication will be reported as an AE or SAE. Abnorma l pregnancy outcomes (eg, 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) or 
genetic abnormalities (whether leading to an elective abortion or not) are always 
considered to be SAEs and will be reported as such. Any post study pregnancy- related 
SAE considered reasonably related to the study treatment by [CONTACT_752944], Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     79 of 85    20 April 2022  reported to the S ponsor as described in Section 10.3.4. While the Investigator is not 
obligated to actively seek this information in former study patients , he or she may learn 
of an SAE through spontaneous reporting. 
• Any female patient who becomes pregnant while participating in the study wil l 
discontinue study treatment or be withdrawn from the study. 
  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     80 of 85    20 April 2022  10.5 Appendix  5: Abbreviations  
Abbreviation  Description  
AE adverse event  
ALT alanine aminotransferase  
ANCOV A  analysis of covariance  
ANMS 
GCSI -DD American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary  
APD action potential duration  
AST  aspartate aminotransferase 
AUC  Area Under the Curve  
AUC 0-last the area under the plasma concentration versus time curve, from time [ADDRESS_1030837] measurable concentration  
AUC ∞ the area under the plasma concentration vs. time curve from time [ADDRESS_1030838] cancer resistance protein  
BMI  Body mass index  
BUN Blood urea nitrogen  
Cmax maximum observed plasma concentration 
eCRF  electronic case report form  
CGI-I Clinical Global Impression -Improvement  
CGI-S Clinical Global Impression -Severity  
CHO  Chinese hamster ovary  
C-SSRS  Columbia –Suicide Severity Rating Scale  
CTCAE  Common Terminology Criteria for Adverse Events  
CYP  Cytochrome P450 
DG diabetic gastroparesis  
DRM  delayed release multiple dose cohort  
ECG  electrocardiogram  
FAS full analysis set  
FBG  Fasting blood glucose  
FDA Food and Drug Administration 
FGID  Functional gastrointestinal disorders  
FSH follicle -stimulating hormone  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-[ADDRESS_1030839] Level  
PAGI -SYM  Patient Assessment of Gastrointestinal Disorders Symptom Severity Index  
PAGI -QOL  Patient Assessment of Upper Gastrointestinal Disorders – Quality of Life  
PD pharmacodynamic(s)  
PGI-C Patient Global Impression of Change  
PGI-S Patient Global Impression of Severity  
P-gp p-glycoprotein  
PK pharmacokinetic(s)  
PRO  Patient -Reported Outcomes  
PT preferred term  
QD once daily  
QTcB  Bazett’s  correction for QT  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     82 of 85    20 April 2022  QTcF  Fridericia’s correction for QT  
RBC  Red blood cell  
SAE  serious adverse event  
SAP statistical analysis plan  
SD standard deviation  
SGOT  serum glutamic -oxaloacetic transaminase  
SGPT  serum glutamic -pyruvic transaminase  
SIB suicidal ideation and behavior  
SoA schedule of activities  
SOC  System organ class  
TB tuberculosis  
Tmax time at which the maximum plasma concentration was observed  
t½ the apparent first -order terminal elimination half -life 
ULN  upper limit of normal  
US [LOCATION_002]  
WBC  White blood cell  
WOCBP  woman of childbearing potential  
λz apparent first order terminal elimination rate constant 
5-HT receptor  5-hydroxytryptamine receptor  
5-HT 4 receptor  5-hydroxytryptamine receptor  4 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     83 of 85    20 April 2022  11 References  
1. Briefing Document for FDA Gastrointestinal Drugs Advisory Committee Meeting 
Regarding Serotonin (5- hydroxytryptamine) Receptor 4 Agonists. 2011. 
2. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical pra ctice. Psychiatry (Edgmont). 2007;4(7):28- 37. 
3. Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nat Rev Dis Primers. 2018;4(1):41. Published 2018 Nov 1. doi:10.1038/s41572- 018-0038- z. 
4. Camilleri M, Parkman H, Shafi M, Abell T, Gerson L. American College  of 
Gastroenterology clinical guideline: management of gastroparesis. Am J Gastroenterol. 
2013:108;18- 37. 
5. de la Loge C, Trudeau E, Marquis P, et al. Cross -cultural development  and validation of a 
patient self -administered questionnaire to assess quality of life in upper gastrointestinal 
disorders: the PAGI -QOL. Qual Life Res. 2004;13(10):1751- 1762. doi:10.1007/s11136-
004-8751- [ADDRESS_1030840] 
Pharmacol. 2021 Jun 4. doi: 10.1002/psp4.[ZIP_CODE]. Epub ahead of pri nt. PMID: 34085769. 
7. Manabe N, Wong BS, Camilleri M, et al. Lower functional gastrointestinal disorders: 
evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 
2010; 22:293- e82. 
8. Movetis NV. Study PRU -[LOCATION_003]- 22. A study to evalua te the long- term tolerability, safety, 
patient satisfaction, pharmacokinetics, and use pattern of oral prucalopride tablets in patients with chronic constipation. Clinical study report. Data on file. 2008.  
9. Movetis NV. Study PRU -INT-17. A study to evaluate the long- term tolerability and 
safety and the pattern of use of prucalopride in patients with chronic pain (cancer and non-cancer), suffering from opi[INVESTIGATOR_2480]- induced constipation. Clinical study report. Data on 
file. 2008   
10. Movetis NV. Study PRU -INT-10. A study to evaluate the long- term tolerability and 
safety of oral prucalopride administered to patients with chronic constipation. Clinical study report. Data on file. 2008. 
11. National Institute for Health and Clinical Excellence (NICE). Prucalopride (Resolor®) for the treatment of women with chronic constipation in whom standard laxative 
regimens  have failed to provide adequate relief. 2010. 
12. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. 
American Gastroenterological Association techni cal review on the diagnosis and 
treatment of gastroparesis. Gastroenterology. 2004;127(5):1592- 1622. 
doi:10.1053/j.gastro.2004.09.055. 
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     84 of 85    20 April 2022  13. Parkman HP, Yamada G, Van Natta ML, et al. Ethnic, Racial, and Sex Differences in 
Etiology, Symptoms, Treatment, and Symptom Outcomes of Patients With Gastroparesis. 
Clin Gastroenterol Hepatol. 2019;17(8):1489- 1499.e8. doi:10.1016/j.cgh.2018.10.050. 
14. Quigley EM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology. 2001;120(1):263- 286. doi:10.1053/gast.2001.[ZIP_CODE] 
15. Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI -SYM) 
in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13(10):1737- 1749. 
doi:10.1007/s11136- 004-9567- x 
16. Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical 
characteristics, psychological and abuse profiles, treatment, and long- term follow -up of 
patients with gastroparesis. Dig Dis Sci. 1998;43(11):2398- 2404. 
doi:10.1023/a:1026665728213 
17. US Food and Drug Administration. Drug approval Package Reglan Tablets. 2017. 
REGLAN (metoclopramide) tablets  (fda.gov)
 
18. US Food and Drug Administration. Drug approval Package Gimoti Nasal Spray. 2021. 
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95269b1f -779c -4ca0 -9f86-
e74e677f9900  
  
Processa Pharmaceuticals, Inc.  Clinical Study Protocol  
PCS12852- GP-01 CONFIDENTIAL   
 
Version 3.0     85 of 85    20 April 2022   
12 Declaration of the Investigator  
Title : A Phase 2A Placebo -controlled, Randomized Dose Response Study of the Safety, 
Pharmacokinetics and Efficacy of PCS12852 on Gastric Emptying Rate Assessed by 13C 
Spi[INVESTIGATOR_752875].  
All documentation for this study that is supplied to me and that has not been previously 
published will be kept in the strictest confidence. This documentation includes this study 
protocol, Investigator's Brochure, electronic CRF (eCRF), and other scientific data.  
The study will not be commenced without the prior written approval of a properly constituted IRB or I EC. No changes will be made to the study protocol without the prior written approval of 
the Sponsor and the IRB or IEC, except where necessary to eliminate a n immediate hazard to the 
patients. 
I have read and understood and agree to abide by [CONTACT_95835]. 
Responsible Investigator of the L ocal S tudy C enter  
 _____________________________________ _____________________ 
Signature  [CONTACT_1782]  
_____________________________________ 
Name ( print  letters)  
_____________________________________ 
Title ( print  letters)  
_____________________________________ 
Institution ( print  letters)  
_____________________________________ 
Phone number  